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Abstract
Exercise and Nrf2 in Chronic Heart Failure
Ahmed Wafi, University of Nebraska Medical Center, 2020
Supervisor: Irving H Zucker, Ph.D.
Increased activation of the sympathetic nervous system (SNS) plays an essential
role in the pathogenesis of cardiovascular diseases such as chronic heart failure (CHF)
and hypertension. Oxidative stress in key brain regions that are involved in maintenance
and regulation of sympathetic vasomotor tone has been implicated in mediating this
sympathoexcitation. One particular mechanism of oxidative stress-mediated increases in
SNS is a reduction of antioxidant enzymes in rostral ventrolateral medulla (RVLM)
neurons. Nuclear factor erythroid 2 related factor 2 (Nrf2) is a master regulator of cellular
redox homeostasis that impacts the expression of antioxidant gene expression. Recent
studies have demonstrated that Nrf2 gene deletion in the RVLM reduces antioxidant
enzymes and increases sympathetic outflow, whereas the upregulation of Nrf2
selectively in the RVLM attenuates sympathoexcitation in CHF mice.
Despite current CHF therapy that targets the renin-angiotensin and adrenergic
systems, the morbidity and mortality of this disease are still extremely high, even with
the best medical management. Exercise training (ExT) is now considered as adjunctive
therapy for CHF. Growing evidence indicates that the beneficial effects of ExT in CHF
are dependent, at least in part, on augmented central antioxidant capacity, which results
in a reduction of sympathetic nervous activity. However, the exact mechanism by which
ExT enhances antioxidant activity in central neurons remains unexplored. We
hypothesized that Nrf2 plays a key role in modulating antioxidant enzymes in the RVLM
and sympathoexcitation in the CHF state. Molecular studies revealed that ExT increased
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Nrf2 and antioxidant enzymes in the RVLM, and reduced sympathoexcitation in mice
with CHF.
Although ExT is an effective and inexpensive way to improve the quality of life in
CHF syndrome, low exercise capacity (exercise intolerance) is a major clinical symptom
of this syndrome that may hinder the beneficial effects of ExT. Previous studies have
shown that increased oxidative stress and reduced antioxidant enzymes in skeletal
muscle causes, at least in part, skeletal myopathy, which contributes substantially to
exercise intolerance in CHF. However, the mechanism by which antioxidant enzymes
are declined in skeletal muscle during CHF is not known. Therefore, we hypothesized
that Nrf2 downregulation contributes to the impaired antioxidant defense in skeletal
muscle during CHF. We further hypothesized that activation of Nrf2, by curcumin,
improves exercise performance in CHF. Indeed, in the CHF mouse model, Nrf2 was
downregulated in skeletal muscle, and curcumin treatment was associated with
improved exercise capacity and upregulated Nrf2 and antioxidant enzymes in skeletal
muscle. Collectively, these data implicate Nrf2 as a key factor in the reduction of
sympathoexcitation and improved exercise capacity in the setting of CHF.
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INTRODUCTION
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Cardiovascular disease
Cardiovascular disease (CVD) is a major health problem in the United States
(US). Approximately 92.1 million American adults had one or more types of CVD in
2014. It is estimated that every 40 seconds, one person in the United States dies from
CVD. In 2014, CVD was the underlying cause of death in over 30% of mortalities and
played a role in half of all deaths. CVD not only affects a large percentage of the
population but also imposes a substantial burden on health care resources. The overall
direct and indirect cost of CVD in the US in 2009 was 313 $ billion. Globally, CVD
remain a leading cause of death, accounting for more than 17.3 million deaths
(approximately 31% of all global deaths) in 2013 and costing $863 billion [1].
Because CVD is a major cause of mortality and morbidity, effective treatment is
critical; however, the treatment effectiveness is limited because most of the current
treatment options target symptoms in order to prevent subsequent cardiovascular events
such as myocardial infarction and stroke. As such, the mandate for clinical and basic
research efforts that target the primary cause is extremely important to understand the
primary mechanisms involved in the pathogenesis of CVD.
CVD encompasses many diseases, including CHF and hypertension, the two
most prevalent forms of CVD. CHF is considered one of the most disabling and deadly
diseases [2]. It is estimated that 5.8 million people are currently diagnosed with CHF,
and each year, around 960,000 new cases are diagnosed with this disease. CHF ranks
among the most costly chronic diseases, with an estimated cost of $30.7 billion in 2012.
In the US, one in nine deaths certificates (300,122) listed CHF as a cause of death in
2011. In 2014, CHF was the underlying cause of 68,626 deaths in the US [3].
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Heart Failure
Heart failure (HF) is a major cause of mortality in the US and many other nations
and characterized by a reduced ability of the heart to pump or fill with blood [1].
Traditionally, CHF was considered solely a hemodynamic disorder. However, because
the therapeutic interventions that improve the hemodynamic status of CHF patients have
no influence on cardiac performance deterioration, the hemodynamic hypothesis was not
sufficient to explain the progression of CHF [4]. The development of the neurohumoral
hypothesis, along with muscle hypothesis, played a role in understanding the
progression of heart failure and demonstrated that heart failure is rather a syndrome and
not a single disorder. Heart failure, therefore, can be defined as a syndrome that
develops as a result of cardiac disease and characterized by symptoms and signs
produced by circulatory, neurohumoral and skeletal muscle response to cardiac
dysfunction [4, 5].
Heart failure is classified as left ventricular, right ventricular, and biventricular
depending on the location of the deficit. Depending on the duration, heart failure is
classified as acute or chronic. Clinically, it is typically classified into two major types
based on the functional status of the left ventricle or ejection fraction (EF): heart failure
with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction
(HFrEF). HFrEF is characterized by reduced LV capacity to pump blood, and hence
oxygen (O2), proportionate with metabolic demands of the body tissues. In HFpEF, the
EF is typically normal, but the LV wall is thickened and stiff [6]. Because the etiology,
progression, and treatment of HFpEF remain poorly understood, the current dissertation
focused purely on HFrEF, which will be termed as CHF for simplicity.
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There are several etiologies (myocardial infarction, hypertension, coronary artery
disease, cardiomyopathies, myocarditis, and valvular heart disease) that may contribute
to the syndrome of CHF, which is characterized by adverse left ventricular remodeling
[7]. This maladaptive left ventricular remodeling occurs due to myocyte loss and an
increased myocardial strain, which results in left ventricular hypertrophy and fibrosis [2].
Thus, the myocardial O2 consumption is increased, and myocardial contractility is
decreased, which causes a reduction in left ventricular EF [2, 8]
Impaired myocardial contractility leads to reduced cardiac output and initiates a
series of compensatory mechanisms to maintain arterial pressure and tissue perfusion.
These compensatory mechanisms are collectively referred to as neurohumoral
stimulation [9-11]. In the early phase of heart failure, these compensatory adjustments
are beneficial and provide adequate peripheral tissue perfusion. However, these
compensatory mechanisms become more intense over time and result in further damage
to cardiomyocytes. The greater the damage to cardiomyocytes, the more compensatory
actions are generated, and a vicious, positive feedback cycle develops (figure 1.1). As
this cycle grows, cardiac reserve capacity is diminished. This reduced cardiac capacity
becomes prominent in certain circumstances, especially during exercise which increases
the load on the heart. This increased load rapidly utilizes the small amount of available
reserve and cardiac output soon fails to meet the demands of the body’s level of activity.
This decreased exercise capacity in heart failure is generally referred to as exercise
intolerance. Decompensated heart failure usually emerges when damage exceeds the
cardiac reserve capacity [10-12]
There are numerous classification systems for CHF which are used for clinical
evaluation of severity. The New York Heart Association (NYHA) classification system,
which classifies the extent of heart failure in a simple way based on the degree of
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exercise limitation, is widely used by clinicians [13]. This classification system ranges
from class I (less severe/asymptomatic) to class IV (most severe; experience symptoms
even at rest) (Table1)
Treatment strategies are different according to each classification and range from
physical activity and dietary changes to high dose medication including diuretics, reninangiotensin system (RAS) inhibitors, and in severe cases, cardiac transplantation or
ventricular assist devices is required [2]. Some of the above treatment options target the
compensatory component of the CHF vicious cycle and not the initiating causal factors.
Strategies that target these primary factors are important for future therapeutics.
NYHA classification system
Class 1

No limitation of physical activity. Ordinary physical activity does not
cause undue fatigue, palpitation, dyspnea (shortness of breath).

Class 2

Slight limitation of physical activity. Comfortable at rest. Ordinary
physical activity results in fatigue, palpitation, dyspnea (shortness of
breath).

Class 3

Marked limitation of physical activity. Comfortable at rest. Less than
ordinary activity causes fatigue, palpitation, or dyspnea.

Class 4

Unable to carry on any physical activity without discomfort.
Symptoms of heart failure at rest. If any physical activity is
undertaken, discomfort increases.

Table 1.1 - The New York Heart Association (NYHA) classification system for extent and
severity of CHF
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Figure 1.1 - The vicious cycle of chronic heart failure
Schematic representation of the progression of chronic heart failure. Decreased cardiac output
increases neurohumoral stimulation including sympathetic nervous system and reninangiotensin system. This increases strain on the heart leading to further decline in the function
and a perpetuation of the cycle.
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Neurohumoral activation in Chronic Heart Failure
Neurohumoral activation in CHF is characterized by activation of the SNS, RAS,
arginine-vasopressin (AVP) system and the counteracting atrial natriuretic peptide (ANP)
and brain natriuretic (BNP) systems [10, 11]. Following a myocardial insult, volume
overload along with impaired sodium (Na) excretion, triggers the atrial
mechanoreceptors, which, apart from the reduction of sympathetic outflow, results in a
vasodilatory, and natriuretic effects [14, 15]. ANP has been shown to increase in
association with asymptomatic left ventricular dysfunction. As such, it plays an important
role in maintaining a compensatory state in CHF [16]. The loss of these counteracting
compensatory mechanisms may signify the beginning of symptomatic heart failure as
the SNS becomes persistently activated. In contrast to SNS activation, which is activated
early in the development of CHF, the RAS is usually triggered when symptoms develop.
In addition, AVP is inappropriately released in more advanced stages when perfusion
pressure is markedly decreased [14]

Increased activation of the sympathetic nervous system
Chronic activation of the SNS has been described as a part of the CHF
syndrome [11, 17-20]. The SNS is normally modified by either inhibitory or stimulatory
feedback mechanisms from a) aortic inhibitory mechanosensitive afferents
(baroreceptors) and cardiopulmonary chemical and mechanosensitive afferents, b)
excitatory afferents activated under certain conditions such as exercise (muscle
metabolic receptors) and ischemic metabolic receptors (e.g. cardiac afferents), and c)
central neuromodulators, which may be either excitatory such as angiotensin II (Ang II)
and norepinephrine (NE) or inhibitory such nitric oxide (NO•) [21].
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Baroreflex dysfunction
The mechanism underlying persistent chronic activation of the SNS is attributed,
in part, to abnormalities of the inhibitory afferents from cardiac chambers, aortic and
carotid arteries. These abnormalities lead to the withdrawal of a sympatho-inhibitory tone
on the vasomotor center in the medulla [11]. In the CHF dog model (chronic
tachycardia), atrial baroreceptor sensitivity is decreased [22, 23], which may contribute,
via increased AVP release, to some of the clinical characteristics of CHF such as
edema, ascites, hyponatremia and renal vasoconstriction [24]. In addition, volume
expansion, which stimulates low-pressure baroreceptors throughout the
cardiopulmonary tree, results in a blunted suppression of renal sympathetic nerve
activity in dogs with CHF [25]. The primary modulator of short term sympathetic
vasomotor tone (arterial pressure) is the arterial baroreflex (ABR) [26]. ABR sensitivity is
depressed in some forms of hypertension as well as in CHF patients and animals [2729]. The underlying mechanism for blunted baroreflex sensitivity involves decreased
discharge sensitivity of the carotid sinus nerve, which is mediated in part by an increase
in Na+-K+ ATPase activity [30, 31]. Central neural components that mediate the ABR
are also involved in blunted baroreflex sensitivity. For instance, in dogs with CHF,
bypassing the receptor ending by stimulating an isolated carotid sinus nerve, resulted in
an impaired baroreflex response [31]. While an impaired baroreflex control of
sympathetic nerve activity is initiated in the early stages of left ventricular dysfunction,
plasma NE was not attenuated after cardiac denervation suggesting that ABR
depression is not necessary for chronic elevation of SNS activity [32, 33]. Growing
evidence suggests that other mechanisms may substantially contribute to persistent
activation of SNS activity. These mechanisms include the skeletal muscle ergoreflex and
the arterial chemoreflex [11].
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Carotid body chemoreflex
Enhanced activation of the carotid body chemoreflex has been shown in humans
and animals with CHF. The underlying mechanism is related to an increased level of
Ang II and decreased NO• in the carotid body [34, 35]. These alterations inhibit voltagegated K+ current, which results in an enhanced carotid body sensitization to hypoxia as
well as elevated resting afferent chemoreceptor activity under normoxic conditions [36].
Furthermore, chronic reduction of blood flow and reduced shear stress in the carotid
body reduces Krüppel‐like Factor 2 (KLF2) expression, a shear stress-sensitive
transcription factor that targets genes associated with antioxidant defense and nitric
oxide synthase (eNOS). [37, 38]. This finding is further supported by evidence that the
degree of augmented carotid body chemoreflex is correlated with the degree of LV
dysfunction [39].
Cardiac sympathetic afferent reflex
Discharge from excitatory cardiac sympathetic afferent nerves is enhanced in
CHF animals [40, 41]. These ischemia sensitive neuronal endings reside mainly in the
epicardial region of the left ventricle. Under normal conditions, these neuronal afferents
have little impact on SNA, however, in CHF these afferent endings become sensitized
and are activated by several chemical mediators released from the ischemic
myocardium [42]. Epicardial application of bradykinin and hydrogen peroxide, as well as
volume expansion, produced an enhanced cardiac sympathetic afferent reflex, indicating
that cardiac sympathetic afferent endings are sensitized in CHF [43, 44]. Furthermore,
the central gain of cardiac sympathetic afferents is enhanced in CHF [40, 41]. This
enhanced gain is mediated by the central increase in Ang II and reduced NO• at the
levels of the NTS, PVN and RVLM [45-47]. In addition, afferent input from cardiac
sympathetic afferents impact the integration of peripheral reflex input at the level of the
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NTS via an Ang II mechanism. Cardiac sympathetic afferents potentiate the peripheral
carotid body chemoreflex activation of sympathetic outflow and contribute to the
impaired baroreflex inhibition of sympathetic outflow in CHF [48, 49].
Exercise pressor reflex
The exercise pressor reflex (ergoreflex) originates from the stimulation of
group III (mechanically sensitive) and group IV (metabolically sensitive) sensory endings
in contracting skeletal muscle. During exercise, ergoreceptor afferent signals travel in
the lateral spinothalamic tract and mediate sympathetic vasoconstriction as well as an
increase in ventilation [50]. While there is a substantial agreement that the ergoreflex is
exaggerated in CHF [50-52], the role of mechanical and metabolic components of the
ergoreflex remains controversial. Human and animal studies suggest that the
mechanical component is sensitized, whereas the metabolic component is blunted in
CHF [53, 54]. Other studies have shown that the metabolic component is enhanced [54,
55]. This controversy in the role the metabolic receptors may be related to the type of
muscle work being done as some studies have utilized static muscle contraction,
whereas others utilized rhythmic exercise to activate sensory afferents endings. For both
rhythmic and static handgrip exercise, a dynamometer was used to measure force
production. The basic difference between the two forms of handgrip exercise is that in
static handgrip exercise, the contraction is isometric, for example, gripping the
dynamometer at 60% of maximal voluntary contraction for a certain period of time,
whereas in dynamic handgrip exercise, repetitive rhythmic contraction is performed [56].
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Abnormalities in central nervous system control of the sympathetic outflow
Studies performed on pacing-induced CHF dogs demonstrate that baroreflex
denervation [57] and ß-adrenergic blockade [33] have no influence on neuro-humoral
drive suggesting that central mechanisms may contribute to elevated neuro-humoral
stimulation. The forebrain, hypothalamus, and brainstem are the major areas that
contain core neuronal circuits which initiate and adjust reflexes to maintain homeostasis.
Figure 1.2 shows the central neuronal pathways that regulate cardiovascular function.
These central neuronal networks are updated continuously on the status of
cardiovascular, respiratory, gastrointestinal, and other vital organs via visceral afferents
that project to the NTS [58]. Circulating hormones and blood born factors sensed by
circumventricular organs such as the subfornical organ (SFO) also contribute to the
regulation of central neuronal networks [59]. A prominent reflex incorporated by these
central autonomic networks is the baroreflex arc in which afferent fibers from highpressure baroreceptors project to the NTS. An increase in arterial pressure stimulates
baroreceptor firing which evokes NTS excitatory projections (glutamatergic) to the
caudal rostroventrolateral medulla (CVLM), which sends inhibitory projections
(GABAergic) to the RVLM [60]. The RVLM has a direct projection to the intermediolateral
(IML) cell column of the spinal cord where it synapses with sympathetic preganglionic
neurons and ultimately end-organ sympathetic nerves. In addition, excitatory interneurons project from NTS to cardio-inhibitory areas (nucleus ambiguous and dorsal
motor nucleus of vagus), which account for the primary cardiac component of the
baroreflex. As mentioned above circumventricular organs such as the SFO and the
median preoptic nucleus, which contain osmosensitive neurons can sense circulating
factors. These centers send projections to hypothalamic nuclei such as the
paraventricular nucleus (PVN), which has a direct projection to sympathetic
preganglionic neurons and to the RVLM. For instance, atrial volume receptors project to
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the NTS, which suppresses PVN activity through GABAergic interneurons resulting in
decreased sympathetic nerve activity to the kidney. The PVN, therefore, plays a key role
in mediating the reduction of sympathetic nerve activity in response to volume expansion
[61]. It is well-established that the PVN is a key mechanism for blood volume regulation.
Atrial mechanoreceptors sense blood volume changes. The signals from these receptors
are conveyed to the NTS by vagal afferents. An increase in the blood volume triggers a
reflex decrease in renal sympathetic nerve activity, which results in renal vasodilation
and increased urine flow and sodium loss [62].
Abnormalities of central neuronal regulation are potential mechanisms for
enhanced central sympathetic outflow in CHF. Major mechanisms for centrally mediated
enhanced sympathetic outflow involve activation of Ang II, angiotensin receptors and an
increased level of reactive oxygen species (ROS) [63, 64]. Other mechanisms also
involved in enhanced central sympathetic outflow such blunted NO•. inhibition of
sympathetic outflow [18], inflammatory cytokines, and activation of excitatory
neurotransmitters [65]. However, a comprehensive discussion of these factors are out of
the scope of this dissertation.

Renin-Angiotensin System
It has long been known that the RAS plays a key role in the progression of CHF
[66] [17] [67]. The RAS is an endocrine system, which plays an important role in
regulating extracellular fluid and electrolyte balance thereby maintaining cardiovascular
homeostasis [12]. The key determinant of RAS activity is renin secretion by
juxtaglomerular cells in the kidney. Renin secretion is stimulated by Low renal perfusion,
decreased NaCl flux sensed by macula densa and sympathetic β1-adrenergic
stimulation of juxtaglomerular cells [68]. Renin regulates the rate-limiting step of RAS by
cleaving angiotensinogen, which is constitutively secreted by the liver, to form
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biologically inert angiotensin-I. Angiotensin-I is then cleaved by the membrane-bound
angiotensin-converting enzyme (ACE) to form biologically active Ang II, which is
considered the primary effector peptide of the RAS system [69]. In addition, angiotensinI can be cleaved by angiotensin-converting enzyme 2 (ACE2) to form Ang-(1-7) and
Ang-(1-9). Ang-(1-9) can be further cleaved by ACE to form Ang-(1-7). Ang II mediates
its cellular effects by binding to G-protein coupled, angiotensin type 1 receptor (AT1R)
and angiotensin type 2 receptor (AT2R). The Ang II-AT1R signaling pathway is complex
and involves phospholipid (phospholipase C), alterations of gene transcription factors (cfos and c-jun), activation of tyrosine kinases, and activation of membrane-bound ROS
generating enzymes such as nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases [70-72]. AT2R and the mas receptor are involved in counteracting the AT1R
actions and thus comprise the protective arm of RAS signaling [73-75]. Indeed, previous
studies from our lab and others have demonstrated the potential therapeutic effect of
ACE2-MasR on cardiovascular diseases such as CHF [76] and hypertension [77].
Pharmacological inhibitors of RAS, such as captopril (ACE inhibitor) and losartan (AT1R
blocker) are widely used in treating CHF and hypertension [78] [79].
Previously, it has been thought that high levels of circulating Ang II in CVD such
as CHF and hypertension do not pass the blood-brain barrier, as this peptide is too large
to have access to the central cardiovascular control areas. However, Biancardi et al. [80]
observed that fluorescent-labeled Ang II can extravasate into the cardiovascular control
areas in the hypothalamus and brain stem along with increased blood-brain barrier
permeability indicating that peripheral Ang II has direct access into central areas of
cardiovascular control. In addition, circumventricular organs in the brain such as the
SFO which lack a blood-brain barrier have an important role in Ang II regulation of blood
pressure due to their ability to sense and detect circulating factors [81, 82].
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It also appears that the area postrema plays a role in chronic hypertension.
Chronic intravenous Ang II infusion (5-10 days) results in a transient increase in the
mean arterial pressure in area postrema ablated rats, whereas in controlled sham-lesion
rats, chronic Ang II infusion results in sustained hypertension [83].
In addition to the effects of circulating Ang II on central neuronal activity, the
brain contains its own RAS. Ganten et al. [84] demonstrated that Ang II is detected in the
brain of nephrectomized dogs, suggesting that the brain RAS is altered independently of
the peripheral RAS. The RAS is also found intracellularly within neurons [85]. This
suggests that the RAS, particularly Ang II acting as a neurotransmitter or
neuromodulator alters neuronal activity, thus affecting sympathetic outflow. In cultured
neurons, AT1R stimulation increases Ca+2 current, while inhibiting both the delayed
rectifier K+ current (IKv) and transient (A‐type) K+ current (IA) and these alterations in ionic
currents were associated with an enhanced neuronal firing [86].
The link between Ang II intraneuronal signaling and increased sympathetic
nervous activity in the setting of CHF has been supported by numerous studies. It is well
accepted that Ang II-induced sympathoexcitation in the setting of CHF is mediated, at
least in part, by reactive oxygen species (ROS) through the AT1R [87-89]

Arginine vasopressin
Circulating plasma levels of AVP is increased in humans with CHF [90, 91] and
animal models of CHF [92, 93]. The precise mechanisms for AVP release from the
posterior pituitary involve factors other than plasma osmolality. For instance, in CHF
patients, reducing plasma osmolality did not reduce AVP concentration [94]. These
factors are related to a decrease in atrioventricular compliance and therefore decreased
in stretch receptor sensitivity that leads to the impairment in baroreceptor-mediated
inhibition of AVP release [94]. Another factor is Ang II which directly stimulates AVP
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release from the posterior pituitary [95]. Plasma levels of AVP are increased in parallel to
an increase in plasma renin activity, possibly due to compromised organ perfusion [91]

Atrial natriuretic peptide
ANP is synthesized in the atria and released in response to atrial stretch. ANP
exhibits a vasodilatory effect via inhibition of NE release. It also exerts a direct
vasodilatory effect as well as a natriuretic effect [11]. ANP is released in the early
asymptomatic stages of CHF in response to increased cardiac filling pressure, thus acts
as a compensatory mechanism to reduce cardiac volume overload. Persistent atrial
stretch, however, impairs atrial compliance and decreases ANP levels, which results in
blunted ANP release in response to atrial stretch [91]. Ventricular brain natriuretic
peptide (BNP) has a similar function to ANP and is released from the ventricular
myocardium in response to ventricular stretch and causes vasodilation and natriuresis
[96]. The rise in BNP seems to be a more accurate measurement compared to ANP in
the detection of left ventricular systolic dysfunction [97], and it is considered an
independent predictor of mortality in CHF patients [98]
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Figure 1.2 - Schematic of cardiovascular control centers in the mouse brain
In the normal condition, CVLM provides a tonic inhibitory control of RVLM neurons which reduces the vasomotor
tone. In the setting of CHF, impaired baroreflex function leads to decreases NTS afferent activity, this results in
removal of the tonic suppression of the RVLM activity from the CVLM and results in increased sympathetic
outflow to end organs. Additionally, central angiotensin signaling, especially in circumventricular organs, increased
sympathetic outflow through PVN and RVLM.
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Rostro-ventrolateral medulla (RVLM)
As mentioned above, increased arterial pressure results in inhibition of vasomotor
medullary area, which contains spinally projecting pre-sympathetic neurons. This group
of pre-sympathetic neurons collectively referred to as RVLM [60]. RVLM neurons are
responsible for the tonic sympatho-excitatory drive for vasomotor tone and considered a
key site for the integration of multiple reflexes that mediate changes in sympathetic
nerve activity and blood pressure [26]. A unique property pf the RVLM is that, unlike
other presympathetic nuclei, it does not send projections to parasympathetic
preganglionic neurons [60], suggesting that the RVLM plays an important role in
controlling sympathetic vasomotor tone.
In anesthetized rats, RVLM excitation markedly increases arterial pressure and
heart rate. Conversely, acute inhibition of the RVLM reduces these parameters to the
same extent as cervical spinal cord dissection [99], this suggests that the basal
vasomotor drive is primarily mediated by the RVLM. Neurons within the RVLM, most
probably the adrenaline synthesizing neurons (C1), are key neurons that influence
sympathetic vasomotor fibers and HR. These neurons have a discharge pattern that is
similar to barosensitive sympathetic efferent and considered an integral part of the
baroreceptor reflex arc [100].
Approximately 50 -70% of pre-sympathetic RVLM neurons are C1 neurons, 80%
of which synthesis glutamate [60]. Intrathecal administration of Kynurenate, a glutamate
receptors antagonist, in the thoracic spinal cord dramatically reduced sympathoexcitatory response produced by RVLM stimulation [101], suggesting that bulbospinal
RVLM neurons use glutamate as a neurotransmitter to excite sympathetic preganglionic
neurons. In addition, 60 to 70% of presympathetic neurons are catecholaminergic
neurons [102], however, 80% of catecholaminergic neurons contain vesicular glutamate
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mRNA[103]. It has been suggested that the bulbospinal catecholaminergic neurons exert
modulatory effects on the activity of sympathetic preganglionic neurons. Experiments on
rats using intrathecal administration of noradrenaline or adrenaline reveal that
catecholamines may stimulate (probably via alpha 1 adrenoreceptors) or inhibit (alpha 2
adrenoreceptor) preganglionic sympathetic neurons [104].
The mechanism by which RVLM neurons generate sympathetic vasomotor tone
is not clear. Historically, two views have been proposed; RVLM neurons have the
capability to display pacemaker-like activity and therefore can generate action potentials
without synaptic input. In contrast, others have suggested that the RVLM requires
synaptic input to generate tonic activity [60]. Angiotensin II and reactive oxygen species
play an important role in regulating the tonic activation of RVLM neurons [63]. Other
substances such as glutamate, catecholamines, acetylcholine, NO. and Substance P
also affect RVLM neuronal activity but are beyond the scope of this dissertation.

Reactive oxygen species (ROS) in the central nervous system
Over the past decade, one of the most prominent notions that have emerged in
the field of cardiovascular research is that ROS act as intracellular signaling
molecules[105]. ROS are simply defined as highly reactive biomolecules that contain O2
[106]. Unlike free radicals, ROS do not always have an unpaired electron, thus, not all
ROS are free radicals. Following a one, two, or three O2 reduction, superoxide (O2.-),
hydrogen peroxide (H2O2), and hydroxyl radicals (HO.) are produced. ROS are produced
by enzymatic reactions, as with production of O2.- by NADPH oxidase (NOX) and
xanthine oxidase, interaction with each other as with production of peroxynitrite (ONOO-)
from the reaction of nitric oxide (NO.) with O2.-, interaction of ROS with metals, as in HO.
production from the reaction of H2O2 with Fe+2, or by mitochondrial electron transport
chain. [107, 108]. The role of ROS in the phagocytotic process was one of the first

19
observations for a physiological role of ROS when it was discovered that ROS are
necessary for the destruction of pathogens. [109] [110]. In fact, if ROS production is
disturbed, patients suffer from a disease known as a chronic granulomatous disease
[111].
Accumulating evidence demonstrates that ROS are not only essential
participants in cell signaling but also play a role in cellular damage and contribute to the
pathogenesis of a number of human diseases [105]. This paradox in the role of ROS as
biomolecules participating in the regulation of cellular function and as cellular toxic byproducts is perhaps related to differences in the concentration of ROS produced.
Excessive production of cellular ROS causes DNA mutation, lipid peroxidation, structural
and functional alterations of proteins and consequently cellular death [112]. As such,
cells have a complex system for protecting against changes in the redox environment.
This system includes a number of antioxidant enzymes such as superoxide dismutase
(SOD), catalase, and glutathione peroxidase. These antioxidant enzymes are distributed
within certain subcellular compartments. For example, SODs are located in either the
cytoplasm (SOD1, CuZnSOD), extracellular space (ecSOD, SOD3) or mitochondria
(SOD2, MnSOD). Catalase and glutathione peroxidase are residing in peroxisomes and
cytoplasm, respectively [58]. When ROS are excessively produced due to disruption
antioxidant enzyme production, overactivation of ROS-generating enzymes, or
mitochondrial abnormalities, a deleterious condition called “oxidative stress” occurs [58].
It is well established that oxidative stress is involved in many pathological conditions
such as CHF and hypertension [113-115].
Harrison and Griendling [116] were the first to demonstrate the relationship
between Ang II and ROS generation in the cardiovascular system in normal and disease
states. Ang II-mediated superoxide (O2•–), generated through NOX enzymes, leads to
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endothelial dysfunction and the pathogenesis of hypertension [116-118]. Because of
accumulating evidence suggesting that ROS mediate a variety of acute and chronic
effects in the cardiovascular system, their role in altering autonomic outflow in disease
conditions has become of interest. Several studies have now shown that ROS stimulates
sympathetic outflow [119, 120]. More importantly, the link between Ang II simulation and
ROS has been supported by numerous studies. In the central nervous system, Ang II
produces ROS from two main sources; NOX enzymes and the mitochondrial electron
transport chain [121]. Ang II induces enzymatic activity and expression of NOX that lead
to enhances O2 reduction to O2•– via the transfer of a single electron from NAD(P)H [58].
Ang II also reduces the activities of complexes I and III of the mitochondrial electron
transport chain, which interfere with electron transport between complexes resulting in
electron leakage and increased generation of O2•– [122]. In addition to NAD(P)H
oxidase and mitochondrial mechanisms in ROS production, an interplay between
NAD(P)H-derived O2•– and the mitochondrial electron transport chain represent another
mechanism of oxidative stress via a ROS- induced ROS mechanism. For instance, in the
RVLM of Wistar Kyoto Rat (WKY) rats, Ang II-mediated increase in oxidative stress
reduced enzymatic activity of the electron transport chain and was associated with
increased mitochondrial hydrogen peroxide (H2O2). Microinjection of the p22phox subunit
antisense into the RVLM prevented the increase in mitochondrial H2O2 after Ang II
treatment, suggesting that NAD(P)H-derived O2•– induces a feedforward dysfunction of
the electron transport chain [122].
The NOX are a family of enzymes consisting of multiple isoforms (Nox1-5, and
DUOX1-2) that are expressed in varied tissues and subcellular specific locations for
each enzyme [123]. Of all Nox enzymes, two that are closely implicated in the
pathogenesis of CVD and have been found to mediate the pressor effect of Ang II are
Nox 2 and Nox 4. While both enzymes are required for the Ang II pressor effect when
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injected into the SFO, only Nox2 was found to be associated with the Ang II-induced
drinking response [124]. The differential role of both Nox’s may be partially attributed to
different subcellular localizations within neurons, as Nox4 is localized to neuron
mitochondrial [125], while Nox2 primarily resides in the plasma membrane[123].
Accumulating evidence indicates that in central neurons that have major control over
cardiovascular function such as the PVN and RVLM, Ang II, binds to AT1R, which
activates Nox2, leading to O2•– production within these neurons which results in
stimulation of sympathetic nervous activity [126-128]. Removal of O2•– by selective
overexpression of CuZnSOD in the mice SFO, a brain area known to be a primary
sensor for blood born Ang II, prevented hypertension and the associated increase in O2•–
indicating that the O2•– is required for the central response to Ang II [129].
In humans, evidence has begun to emerge that suggest a role for ROS in the neurohumoral activation associated with CHF. A clinical study [130], has shown that acute
antioxidant treatment with vitamin C improves baroreflex function, most likely by
improving endothelial dysfunction and promoting vasodilation. Furthermore, multiple
evidence suggest that antioxidant therapy delivered to the carotid sinus [131] as well as
in central autonomic nuclei such as the RVLM [132, 133] improves baroreflex sensitivity
in animals with CHF, indicating that antioxidants contribute to neuronal control of
baroreflex function. SOD protein microinjection into the RVLM of anesthetized swine
produced a reduction in renal sympathetic nerve activity. This evidence supports the
involvement of ROS in the regulation of sympathetic nerve activity [134]. Our lab has
shown a relationship between Ang II and ROS as contributors to sympathoexcitation in
CHF. In a rabbit model of pacing-induced CHF, intracerebroventricular administration of
Ang II increased renal sympathetic nerve activity which was associated with an
upregulation of Nox2 and increased Nox2-dependent superoxide anion in the
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RVLM.[113] These responses were abolished by the administration of the SOD mimetic
tempol or the Nox2 inhibitor, apocynin. Furthermore, the expression of both CuZn SOD
and MnSOD was downregulated in the RVLM of rabbits with CHF and overexpression of
CuZn SOD into the RVLM decreased baseline sympathetic nerve activity [113, 133].
These findings suggest that in the RVLM of rabbits with CHF, pro-oxidant mechanisms
contribute to sympatho-excitation and that the enhancement of antioxidant pathways
may contribute to the normalization of sympathetic nerve activity in CHF.
A major mechanism by which ROS mediates an increase in sympathetic outflow
by central neurons in CHF is a redox modulation of ion channels such as Ca+2 and K+
channels that play an important role in the generation of action potentials and neuronal
excitability and have been shown to be regulated by ROS [135]. Evidence from both in
vivo and in vitro studies has shown that ROS, especially O2•–, derived from Nox2 and
mitochondria are involved in Ang II-mediated modulation of Ca+2 and K+ channels [136138]. While O2•– acts as an intermediate for Ang II-induced neuronal ion channel
modulation, as discussed above, NO• mediates Ang-(1-7)-induced increase in neuronal
K+ current [139], thus acting as a sympatho-inhibitory molecule in the central neurons.
Because of the opposite effects of O2•– and NO• on neuronal ion channels, it is plausible
that the balance between these 2 radicals is crucial in maintaining sympathetic outflow
given the fact the reaction between O2•– and NO• is diffusion-limited. As such, the
downregulation of NO• in the central neurons such as in the PVN and RVLM [140, 141],
is partially caused by increased O2•– . Another mechanism by which ROS increases
sympathetic outflow in CHF involves astrocytes and glutamate signaling. Ang II has
been shown to inhibit astrocyte glutamate transporter function, leading to increased
extrasynaptic glutamate and thus excitation of presympathetic neurons [142]. Given the
fact that ROS impairs glutamate transporters in cortical astrocytes leading to
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neurotoxicity [143], it is possible to speculate that Ang II induces ROS production in
central brain areas that contribute to inhibition of glutamate transporter function.
The intracellular signaling pathway through which ROS mediate an increase in
sympathetic outflow involves a number of redox-sensitive proteins. Some of the
upstream mediators include protein kinase C (PKC) and redox-sensitive Calcium
Calmodulin-dependent protein kinase (CaMK) proteins. Furthermore, inhibition of these
two proteins in primary neurons cultured from rat hypothalamus abolished the Ang IImediated reduction in K+ current [137]. NOX 2 represents a critical link between Ang IImediated production of these two proteins and ROS generation. One of the important
downstream mediators of ROS signaling is mitogen-activated protein kinase (MAPK). In
the RVLM, Ang II-mediated activation of PKC-NOX-ROS signaling cascade has been
shown to trigger activation of p38MAPK, which in turn, mediates a short-term pressor
response of Ang II via enhancement of glutamate release to RVLM neurons [144]. In
addition, ROS-mediated activation of extracellular signal-regulated protein kinase
(ERK)1/2 has been shown to mediate the long-term pressor response of Ang II. For
instance, in rabbit RVLM, the Ang II-AT1R-mediated activation of PKC lead to NADPHdependent phosphorylation of ERK, which mediates the upregulation of AT-1R mRNA
[145].
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Exercise training
It has been generally well accepted that habitual physical activity is inversely
associated with all-cause mortality and CVD mortality. Initial observations of Morris. et
al., in 1953 [146] , illustrated that workers who are physically active had a lower coronary
heart disease mortality rate compared with their sedentary co-worker counterparts.
Multiple observational and epidemiological studies have been conducted, yielding similar
results; physically active individuals have lower rates of coronary heart disease and CVD
than inactive individuals [147-149]. Based on these studies, and subsequent multiple
lines of evidence, the American Heart Association in 1992, recognized physical inactivity
as an independent risk factor for CVD [150]. While the inverse association of physical
activity and CVD is mainly derived from observational studies, and therefore, cannot
prove a cause and effect relation, multiple randomized controlled trials support a causal
relation [148, 151]. Given the relationship between SNS overactivity and CVD mortality,
it becomes apparent that physical activity-induced alteration of SNS in otherwise healthy
individuals is important in reducing CVD incidence. More importantly, it has been
suggested that physical activity has multiple beneficial effects on the cardiovascular
system in disease states. These effects include reduction of blood pressure and
sympathetic outflow in humans [152-154], and animals [155, 156]. CVD such as
hypertension and CHF are associated with overactivity of the sympathetic nervous
system [9, 58]. Because morbidity and mortality in hypertension and CHF are often
associated with elevation of SNS activity, it is likely that the beneficial effects of physical
activity are related, at least in part, to the reduction of SNS activation.
Prior to 1990, ExT was thought to be detrimental to patients with CHF, regardless
of severity. In fact, exercise was thought to further worsen left ventricular function [157].
While this is still true for patients with severe CHF, there is a spectrum of CHF patients
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who are ambulatory and able to perform ExT. For these patients, ExT tends to be
beneficial, not only in terms of quality of life, but there are now data that suggest it
prolongs life [158-160]. Coats et al. [161] performed the first randomized controlled trial
of ExT in patients with stable CHF in 1990, demonstrating that 8 weeks of ExT increased
VO2 max by 18%. After this groundbreaking finding, attention was gradually drawn to the
beneficial effects of ExT in CHF patients. During the period from1999 to 2010, multiple
randomized control trials [160, 162-165] and metanalyses [165, 166] [166, 167]
suggested that ExT has beneficial effects on quality life, functional capacity,
hospitalization and mortality. The largest-scale prospective study to date is the
Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). In this
randomized, multicenter controlled trial, 2331 patients with stable CHF (EF≤34%), were
randomly assigned to usual care plus aerobic ExT or to usual care alone. The results of
HF-ACTION clearly indicated that an ExT program over 2.5 years significantly improved
quality of life. While all-cause mortality and hospitalization were not altered by ExT, there
was a borderline significant reduction in cardiovascular mortality and CHF
hospitalization. After adjustment for 4 confounding factors, ExT was associated with a
significant reduction of all-cause mortality and hospitalization [168-170]. Collectively,
these studies indicate that ExT is a safe and effective nonpharmacological strategy for
treatment of CHF. While there is an agreement that ExT is beneficial for CHF patients,
the underlying mechanisms for these effects are not fully clear.

Exercise intolerance
Given that LV function is impaired in CHF, it was historically presumed that LV
dysfunction is related to the degree of exercise intolerance. As such, the prevailing
hypothesis in the past was that hemodynamic factors in CHF mediate exercise
intolerance. Furthermore, the limits of physical activity occur at the maximal oxygen
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uptake (VO2 max) which, by definition, equals the product of heart rate, stroke volume,
and arteriovenous oxygen difference (Fick principle) [171]. Therefore, it was presumed
that reduced peripheral blood flow would result in under perfusion of exercising skeletal
muscle and consequent early onset of intramuscular acidosis, which triggers the
ergoreflex and hyperventilation [172]. However, several interventional studies
demonstrated that even after pharmacological improvement of blood flow and O2
delivery, exercise capacity in CHF patients did not improve [173-175]. In addition,
correlational studies failed to show a significant relationship between exercise capacity
and cardiac function [176, 177]. These findings, therefore, suggest that the impaired
cardiac function at rest is not a primary cause of reduced exercise capacity in CHF
patients.
After the advent of the muscle hypothesis promoted by Coats [52], attention has
been drawn toward the peripheral consequences of CHF. Peripheral vasoconstriction is
initially an important adaptation in heart failure, and it serves to maintain perfusion of
vital organs such as the brain [178]. However, persistent, long term vasoconstriction
becomes exaggerated and results in several adverse adaptations in peripheral tissues
such as skeletal muscle [179]. The underlying mechanism for CHF-induced
vasoconstriction involves overactivation of endocrine and nervous systems (i.e. RAS and
sympathetic nervous system). Furthermore, during exercise, sympathetic overactivation
is further increased due to altered sensitization of nerve endings (group III and IV
afferents) within skeletal muscle [180, 181]. Also, vascular resistance in skeletal muscle
fails to decrease during exercise in CHF patients, and flow to non-exercising tissues is
maintained at the expense of exercising muscle (impaired normal distribution of cardiac
output during exercise) [182, 183]. This occurs in a way that is independent of reduced
cardiac output and is related, in part, to the reduction in the bioavailability of biochemical
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mediators such as NO• that oppose local vasoconstriction [184, 185]. Collectively, these
effects result in impaired blood flow and its proper redistribution toward skeletal muscle
during exercise. The consequence of these effects is that during exercise, skeletal
muscle O2 demands are not met, which leads to a greater reliance on anaerobic
metabolism and early onset of myofibrillar acidosis [186]. This and other anaerobic
byproducts, such as lactic acid, potassium (K+), adenosine, and bradykinin trigger the
ergoreflex, which stimulate ventilation and increases the work of breathing [187]. This
reduces skeletal muscle blood flow even further as hyperactivated breathing muscles
compete with locomotor muscles for blood and O2 [188]. The under perfusion as a result
of sympathetic overactivation not only impairs oxidative metabolism, but also provokes
oxidative stress and inflammation, which are associated with skeletal muscle wasting,
alteration in excitation-contraction coupling, and abnormal metabolism [172, 189-192].
These features together are collectively referred to as skeletal myopathy.

Skeletal myopathy
The salient features of skeletal myopathy in CHF include muscle fiber atrophy, a
shift in muscle fiber type from slow, oxidative to fast glycolytic types, decreased capillary
number per muscle fiber, a rapid increase in muscle acidosis, and decreased
mitochondrial density and oxidative enzyme content [190]. These features of skeletal
myopathy correlate not only with the severity of CHF [190, 193] but also with the degree
of exercise impairment [194-196]. SNS overactivation in CHF is a major contributor to
skeletal myopathy via mechanisms such as tissue hypoxia, oxidative stress,
inflammation, altered skeletal muscle metabolism, and excitation contraction
abnormalities [190]. Sympathetic hyperactivity-induced vasoconstriction leads to skeletal
muscle hypoperfusion and ischemia, followed by ROS release, which triggers muscle
inflammation in part via nuclear factor kappa-light-chain-enhancer of activated B cells
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(NF-κB) signaling pathway [197]. Proinflammatory cytokines such as tumor necrosis

factor-alpha (TNFα) has been shown to induce skeletal muscle atrophy in CHF via
apoptosis [198]. Also, increased SNA leads to abnormal metabolism. For instance, the
infusion of epinephrine into skeletal muscle during isotonic tetanic contraction increases
the production of lactic acid in healthy humans and animals [199, 200]. In CHF, NE
release during exercise is accentuated, and lead to the production of lactic acid at a
lower workload [201]. Furthermore, increased ROS levels disrupt excitation-contraction
coupling by oxidizing the contractile machinery such as SERCA, which impairs Ca+2
sequestration after Its release from the sarcoplasmic reticulum [202].

Oxidative stress in CHF-induced skeletal myopathy
Both ROS production and content are enhanced in skeletal muscle of animals
with CHF [203, 204]. There are numerous sources of ROS generation in skeletal muscle.
These sources include mitochondrial, which is a predominant source of ROS in skeletal
muscle, Nox2, NO•, and xanthine oxidase [205]. Enhanced ROS production in skeletal
muscle substantially contributes to the CHF skeletal myopathy by altering both structural
and functional quality of muscle proteins [206]. A major characteristic of skeletal
myopathy in CHF is atrophy, which is partially mediated by oxidative stress, resulting in
a reduction of myofibrillar protein synthesis and/ or increased protein degradation [207].
For instance, oxidative stress interferes with PI3K/AkT/mTOR signaling, which is a major
pathway involved in myofibrillar synthesis. Also, oxidative stress impairs the mammalian
target of rapamycin (mTOR) assembly, and therefore, prevents phosphorylation of
downstream proteins involved in myofibrillar protein synthesis [208]. Furthermore,
oxidative DNA damage activates tumor protein 53 (P53) which has been shown to inhibit
mTOR [209]. Concerning proteolysis, growing evidence demonstrates that oxidative
stress promotes skeletal muscle protein breakdown through activation of the ubiquitin
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proteasome system (UPS). For instance, exposure of myotubes C2C12 to H2O2
upregulated the expression of ubiquitin ligase (E3) enzymes atrogen-1and musclespecific RING finger protein 1(MuRF1) enzymes [210]. Atrogen-1 not only promotes
degradation of MyoD, a master regulator of skeletal myogenesis, but also involved in
sarcomeric protein degradation [211]. MuRF1 ubiquitinates multiple structural proteins of
skeletal muscle such as actin [212] myosin heavy chains [213] and myosin light chains
[214]. Furthermore, by oxidizing skeletal muscle proteins, ROS enhances its
susceptibility to protease-mediated degradation. By using purified protease, Davies et al.
were the first to demonstrate that the oxidative modification of bovine serum albumin
(BSA) protein enhances its susceptibly to proteolytic degradation [215]. This finding has
been expanded by others, it is now well established that oxidative stress-mediated
oxidized myofibrillar proteins are promptly degraded by several proteases including the
20S proteasome and caspase 3 [216, 217].
In addition to atrophy, the decreased strength in CHF-induced skeletal myopathy is
caused by alterations in the contractile proteins. Reid et al. [218] were the first to
demonstrate a relationship between redox balance and muscle force production. They
developed a theoretical model which predicts that a deviation from the optimal redox
state leads to a loss of muscle force production. In agreement with this model,
subsequent studies have shown that a low basal level of ROS in skeletal muscle is
essential for normal force production[219]. Furthermore, a modest increase in skeletal
muscle ROS increases force production [218]. However, this positive impact of ROS on
muscle force production is reversed when ROS concentration becomes very high [218].
Proteins involved in excitation-contraction coupling, such as sarcoplasmic endoplasmic
reticulum 2 (SERCA2), and ryanodine receptor 1 (RyR1), are redox-sensitive targets in
skeletal muscle [218]. As such, oxidative stress in skeletal muscle in the CHF state may
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lead to Ca+2 cycling abnormalities and therefore, reduced skeletal muscle force
production and muscle fatigue [220]. Furthermore, oxidative stress reduces myofibrillar
Ca+2 sensitivity [221] and impairs contractile function. For instance, in soleus muscle of
rats with CHF, the velocity of actin filament shortening was negatively correlated with
oxidized myosin heavy chain, indicating that oxidative stress may contribute to
depresses skeletal muscle performance [222]. We understand that oxidative stress also
impairs cardiac function, but since the focus of this dissertation is on Nrf2 in the brain
and skeletal muscle, we will not discuss oxidative stress in the heart.

Nrf2/Keap-1 signaling pathway
Initial observations in 1986 in the cancer chemoprevention field demonstrated
that 2 (3)-tert-butyl-4-hydroxyanisole (BHA) has a protective effect against
carcinogenesis [223]. The underlying mechanism for the BHA anticancer property is, in
part, due to the antioxidant effect of BHA as well as upregulation of certain antioxidant
enzymes, which can detoxify a broad range of carcinogenic compounds [224]. BHA
along with other compounds such as phenolic antioxidants, polycyclic aromatics, and
coumarins were later identified as inducers of these antioxidant enzymes. These
molecules share a common property of modifying sulfhydryl groups (-SH) by oxidation,
reduction, or alkylation [225]. A low non-lethal dose of -SH reactive inducers evokes a
coordinated increase in antioxidant enzymes level and activity. This cellular adaptation is
called electrophile counterattack response [226]. Based on these observations, it was
suggested that the cellular proteins -SH group acts as a cellular sensor that reacts with
the inducers to produce the cytoprotective counter response.
The susceptibility of the -SH for oxidation is determined by the dissociation
constant (Pka). At the physiological pH, the reactivity of thiol is widely varied depending
on its Pka. Thiols with low Pka tend to exist in the thiolate anion form (S-), thus are more
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likely to be oxidized by ROS [227, 228]. Some oxidation products of the thiols, such as
sulfenic acids and occasionally, sulfinic acid are reversible, which provide a mechanism
for regulation of cell signaling [229]. For instance, reversible oxidation of protein thiols
has been shown to modulate ion channel activity [230], protein kinases [231],
phosphatases [232], and transcription factors [233]. On the other hand, some thiol
oxidation are irreversible, for example, sulfinic acid oxidation to sulfonic acid is
irreversible and as such, the modified protein loses its function and is degraded [234].
Therefore, the reversible oxidation of the thiol groups is an important mechanism by
which ROS can modify cell signaling that results in cytoprotection. An important thiolbased effector for maintaining redox homeostasis is the Keap1-Nrf2 system (Figure 1.3),
which plays an essential role against oxidative stress. Both Nrf2 and Keap1 proteins
contain thiol group and the oxidation of both proteins are implicated in the regulation of
this system.
The enhanced phase II antioxidant enzyme activity is, in part, attributed to the
increased transcription of their genes. While these antioxidant enzymes are under
transcriptional control of the ARE, the transcriptional factors for the ARE were unknown
until Nrf2-null mice were established in 1997 [235]. It was found that induction of phase II
antioxidant enzyme induction by BHA was abrogated in Nrf2-null mice. The regulator of
Nrf2 activity was soon discovered in 1999 when a new thiol rich protein was isolated and
named Kelch-like ECH-associated protein 1 (Keap1). Thus, the Keap1-Nrf2 system is a
two-component system where Keap1 acts as a sensor for ROS whereas Nrf2 is an
effector for coordinated activation of antioxidant enzymes genes expression. In the
cytoplasm, Keap1, along with Cullin3 (Cul3) form a ubiquitin E3 ligase complex and
polyubiquitinate Nrf2, which is then degraded by the proteasome system. In unstressed
conditions, Nrf2 is constantly degraded. However, upon ROS exposure, the -SH of
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cysteine residues of Keap1 are modified, which results in reduced activity of the ubiquitin
E3 ligase activity of the Keap1-Cul3 complex and Nrf2 stabilization. Nrf2 then
translocates to the nucleus, dimerizes with the small musculo-aponeurotic fibrosarcoma
(sMAF), binds to ARE and initiates the transcription of a battery phase II antioxidant
enzymes genes.
Nrf2 is a member of the mammalian cap ‘n’ collar (CNC) transcription factor
family that contains a well-conserved basic region-leucine zipper (bZIP) motif. The CNC
transcription factor family contains P45, Nrf1, Nrf2, Nrf3, BACH1, and BACH2. [236]. As
its family name indicates, Nrf2 contains a basic region responsible for the DNA binding,
and leucine zipper that mediates dimerization with sMAF protein.

Keap1 dependent regulation of Nrf2
Nrf2 structure consists of multiple functional domains: Neh1 (Nrf2-ECH homology
domain-1) to Neh6 (Figure 1.4). Different domains mediate different functions, for
instance, Neh1 mediate DNA binding and dimerization, whereas Neh3, Neh4, and Neh5
have a role in transcriptional activation. Nrf2 lacking Neh2 domain exhibited an
increased transcriptional activity suggesting that there is an inhibitory molecule that
interacts with the Neh2 domain. Two-hybrid screening analysis was used to isolate
Keap1 as an inhibitory Neh2 interacting protein [237]. Thus, Keap1 acts as a recognition
component of the ubiquitin E3 ligase complex and therefore creates the inducible nature
of the Nrf2 function. Under normal conditions, Nrf2 is constitutively degraded through the
proteasomal system, which maintains the amount and the activity of the Nrf2 at a low
level. The underlying mechanism for Nrf2 ubiquitination in the normal, unstressed
condition is related to the structural orientation of the Cul3-Keap1-Nrf2 complex. The
DLG and ETGE motifs in the Neh2 domain of the Nrf2 are critical for interaction with the
Keap1 DC domain. Each motif interacts with its own Keap1 DC domain. This conjugation

33
of Nrf2 with the keap1aligns the lysine residues between the DLG and ETGF motifs and
facilitate Nrf2 ubiquitination by adding ubiquitin groups on lysine in the Neh2 domain of
Nrf2 [236]. The ROS-induced modification of Keap1 cysteine residues disrupts the
activity of the Keap1-Cul3 E3 ligase complex, which allows Nrf2 to accumulate in the
nucleus [236]. Thus, the reactive cysteine residues render keap1 as a critical redoxsensitive biosensor for the regulation of Nrf2.
Keap1 deficient mice died within three weeks after birth due to malnutrition
resulting from esophageal stenosis. The phenotypes of the Keap1-null mice and
subsequent lethality were completely rescued by the disruption of Nrf2 [238]. Transgenic
expression of Keap1 with mutant cysteine 273 (Cys273) or Cys288 failed to rescue the
lethality of the Keap1 null mice indicating that Cys273 and Cys288, located in the IVR
domain of Keap1, are essential for constitutive repression of Nrf2 activity in vivo. In
contrast, Cys151 mutant retained the ability to repress Nrf2 activation, but it had reduced
Nrf2 activation in response to an oxidative insult. This indicates that Cys151, located in
the BTB domain of Keap1, mediates Nrf2 activation in response to oxidative damage
[236]. These results collectively demonstrate the importance of cysteine residues in
maintaining Keap1 function, such that in a quiescent condition, Nrf2 is repressed, and in
response to oxidants, becomes activated [238].
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Figure 1.3 - Schematic overview of Nrf2 pathway
Mechanisms that has been shown to be either Keap1 dependent or independent regulates
Nrf2. In Keap1 dependent mechanisms, modification of one or more cysteine residues results
in Nrf2 activation and nuclear translocation where it binds to ARE and increases the
expression of cytoprotective genes. In Keap1 independent mechanisms, Nrf2 is regulated at
the transcriptional level (1), by coactivators or other transcriptional factors such as NF-κB. At
posttranscriptional level (2) by miRNAs. Post-transcriptional mechanisms (3) via Nrf2
phosphorylation (P), and ubiquitination (Ub). Post-translational modification affects Nrf2
differently; (PKC, MAPK, ERK) affects Nrf2 interaction with Keap1; (GSK3β/βTrCP) induce Nrf2
nuclear export and ubiquitination. A number of proteins, such as P21, have been identified to
compete with Nrf2 for Keap1 binding.

35

Figure 1.4 - Domain structures of Nrf2 and Keap1
Nrf2 has six domains, Neh1 to Neh6. Nrf2 interacting molecules are shown in green boxes above
their interacting domain. Keap-1 has three domains; DRG domain that mediate interaction with
Nrf2, BTB and IVR that mediate homodimerization and CUL3 interaction.
DOI: (10.1152/physrev.00023.2017.
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Keap1 independent regulation of Nrf2
Phosphorylation of Nrf2 is one of the main mechanisms for the Keap1
independent Nrf2 regulation. Nrf2 contains several serine, threonine, and tyrosine
residues which can be phosphorylated by various kinases such as glycogen synthase
kinase 3 β (GSK3β), AKT, PKC, ERK and MAPK [239]. These kinases differentially
regulate Nrf2 with some kinases activating Nrf2, whereas others facilitate Nrf2
degradation.
Oxidative stress has been shown to activate GSK3β, which subsequently
phosphorylates a member of the src family protein (Fyn), resulting in the accumulation of
p-Fyn in the nucleus and subsequent phosphorylation of Nrf2 at tyrosine 568 residue.
Phosphorylated Nrf2 interact with exportin-1 and exported outside the nucleus [240].
Furthermore, GSK3β has been shown to phosphorylate directly the Neh6 domain, which
creates a motif that is recognized by β-transducin repeat-containing protein (β-TrCP)
and therefore targets Nrf2 for ubiquitin-proteasome degradation [241]. Mice subjected to
five intraperitoneal injections of the GSK3β inhibitor, SB216763, exhibited an increase in
Nrf2 protein levels in the liver and hippocampus. More importantly, in the hippocampus
of mice with conditional neurons specific depletion of GSK3β, the Nrf2 protein level was
increased [242]. GSK3β therefore, is considered a key regulator of Nrf2 and may act as
a common downstream effector of some Nrf2 inducers. For instance, in mouse
embryonic fibroblast cells lacking Keap1, the Nrf2 inducer, nordihydroguaiaretic
acid (NDGA) activated Nrf2 through activation of AKT, ERK and MAPK kinases, which
lead to inhibitory phosphorylation of GSK3β, resulting in substantial reduction of Nrf2
phosphorylation and degradation [243]. Furthermore, mice treated with dimethyl
fumarate (DMF) by oral gavage for 3 weeks increased Nrf2 in hippocampus by inhibition
of GSK3β via stimulation of PI3K/AKT signaling pathway [244]. Another kinase pathway
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that has been implicated in Nrf2 activation is PKC, which has been shown to
phosphorylate Nrf2 at Ser-40, leading to its dissociation from Keap1 [245]. However, a
Nrf2 Ser-40 mutant could not be phosphorylated by PKC and Nrf2 remained associated
with Keap1. Furthermore, the phosphorylation and subsequent dissociation of Nrf2 from
Keap1 was abolished by PKC inhibitors [246].
In addition to phosphorylation, other post transcription modifications contribute to
the regulation of Nrf2. Intranuclear proteins (co-activators) may increase or decrease
Nrf2 binding to ARE by interacting with Nrf2 and tethering it to the transcriptional
machinery or by chromatin remodeling that facilitates assembly of the transcriptional
initiation complex. For instance, CREB binding protein (CBP) has been shown to act as
a co-activator of Nrf2 in the nucleus and is also able to promote Nrf2 acetylation of lysine
residues within Neh1 binding domain of Nrf2, resulting in enhanced ARE binding activity
in vitro [247]. Additionally, micro RNAs (miRNAs) have been demonstrated to be
involved in Nrf2 regulation. Our lab has previously shown that six weeks after
myocardial infarction, Nrf2 was downregulated in the heart, and paradoxically, the
transcription of Nrf2 was increased. Several miRNAs including microRNA-27a,
microRNA-28-3p, and microRNA-34a were upregulated in the left ventricle of the
infarcted hearts suggesting that increased local myocardial infarction-induced
upregulation of MiRNAs may contribute to inhibition of Nrf2 translation [248]. The
presence of an ARE binding site in the promoter of Nrf2 is suggestive of the ability of
Nrf2 to regulate its own transcription. In accordance with this, direct binding of Nrf2 to its
promoter region was demonstrated in murine keratinocytes using chromatin
immunoprecipitation assay. Furthermore, the overexpression of Nrf2 increased the
activity of a luciferase reporter assay, whereas mutant Nrf2 repressed the activity of the
luciferase reporter [249]. This evidence that Nrf2 activates its own transcription is
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suggestive of a positive feedback loop, leading to enhanced cell defense. Also, negative
regulatory feedback between Nrf2 and Keap1 exists; the Keap1 promoter contains a
binding sequence for Nrf2, thus Nrf2 regulates Keap1 by controlling its transcription,
whereas Keap-1 controls Nrf2 via proteasomal degradation [250].

Cross talk
Nuclear factor k-light-chain-enhancer of activated B cells (NF-κB) is a redoxsensitive transcription factor that contributes to the regulation of the Nrf2 pathway. In
unstressed cells, (NF-κB) is primarily located in the cytoplasm bound to its inhibitor IκB.
NF-κB inducers such as Ang II, TNF and H2O2 can stimulate IκB kinase, which results in
dissociation of NF-κB and its translocation to the nucleus [251]. Under normal
conditions, an interplay between Nrf2 and NF-κB provides a coordinated response to
oxidative stress to confer cellular protection. However, in several chronic diseases
including CHF, the interplay often leads to an opposite effect such that Nrf2 is, in
general, downregulated whereas NF-κB is hyper-activated. Nrf2 downregulation is
attributed, at least in part, to hyper-activation of NF-κB, which can inhibit Nrf2 expression
in several ways; NF-κB competes with Nrf2 for creb binding protein (CBP) binding in the
nucleus thus preventing Nrf2 binding to ARE, also, NF-κB recruit histone deacetylase 3
(HDAC3), which has been shown to compete with Nrf2 for binding with sMAF [252]. On
the other hand, Nrf2 has been implicated in the regulation of NF-κB via attenuation of
IκB phosphorylation. For instance, NF-κB activation, as well as pro-inflammatory
cytokines are increased in the lung of Nrf2 knock out mice [253]. Furthermore, Nrf2
antagonizes pro-inflammatory genes expression such as interleukin 6 (IL6) and
interleukin 1 β (IL-1β) [254]. As such, in addition to the classical antioxidant function,
Nrf2 has an anti-inflammatory function attributed, in part, to crosstalk with NF- κB and
direct regulation of pro-inflammatory genes.
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Cross-talk with autophagy is another proposed mechanism that contributes to the
regulation of Nrf2 in the Keap1 dependent pattern [255]. An increase p62, which is a
cargo receptor for selective autophagy directly interacts with Keap1, which enables p62
to compete with Nrf2 for Keap1 binding and thus activation of Nrf2 and increased Nrf2
target gene transcription [236]. Furthermore, mutant p62 overproduction, which loses its
ability to bind with Keap1, did not affect Nrf2 activation, indicating that the upregulation
of Nrf2 by p62 is Keap1 dependent [256].

Nrf2 activators
Almost all currently known Nrf2 activators are inhibitors of Nrf2-Keap1 interaction
and they are believed to react with the -SH of cysteines in the Keap1 by oxidation or
alkylation [236, 245], which alters the conformation of Keap1, resulting in a cessation of
Nrf2 ubiquitination. Currently, Nrf2 activators are classified into ten classes based on
their chemical structure and the nature of reaction with cysteine sulfhydryl groups.
Regardless of chemical structure, all Nrf2 activators share a common feature of forming
a covalent adduct with Keap1 cysteine residues with different potency and specificity
[257]. Covering all Nrf2 activators is beyond the scope of this dissertation, however, the
two activators which are relevant to the current work include exercise training and
curcumin which will be discussed below.

Exercise
There is increasing evidence indicating that Nrf2 plays a key role in how oxidative
stress mediates the beneficial effects of exercise training [258, 259]. ROS generation
during physical exercise induce endogenous antioxidant enzymes that, to a great extent,
are regulated by Nrf2. Regular aerobic ExT in rodents has consistently been shown to
activate Nrf2 signaling across several tissues including the brain [260] skeletal muscle
[261], myocardium [262], kidney [263], and liver [264]. The exercise-induced
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upregulation of Nrf2 is necessary for the ExT-induced adaptation. For instance, after 5
weeks of treadmill ExT, mice deficient in Nrf2, showed reduced exercise capacity,
mitochondrial biogenesis and antioxidant enzymes in skeletal muscle [259]. More
importantly, ExT can restore Nrf2 levels in conditions where Nrf2 signaling is already
impaired. Reduced Nrf2 level in the myocardium of old (23 months) mice was restored
after 8 weeks of moderate-intensity exercise[262].
Inflammation appears to be largely responsible for Nrf2 dysregulation in CHF via
activation of pro-inflammatory cytokines and their downstream mediators such as NF-κB.
Sustained inflammation activates GSK-3β, a kinase that plays a role in Nrf2 degradation
[265]. ExT may impact these pathways since it has been shown that ExT reduces proinflammatory cytokines [266], NF-κB expression [133]. ExT is also associated with
activation of the AKT-PI3K signaling pathway, which inhibits GSK-3β, thus preventing
Keap1-independent degradation of Nrf2 [236, 267].

Curcumin
Natural products have historically proven their value as a source of molecules
with therapeutic potentials. Clinical pharmacological studies of these natural products,
which were predominantly derived from plants, were the basis for some of the commonly
used medicines such as aspirin and morphine [268]. Such utility was recognized on a
larger scale as the discoverer of artemisinin, a natural product discovered from a
traditional Chinese medicine, shared the Noble Prize in Physiology and medicine in
2015. Artemisinin was developed into an effective therapy for Plasmodium falciparum
malaria [269]. Naturally occurring polyphenols such as curcumin and resveratrol have
gained importance because of their abundance, low cost, and minimal side effects
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene3,5-dione) is a
constituent of the traditional medicine known as turmeric. Major constituents of turmeric
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are diarylheptanoids (collectively known as curcuminoids) which make up approximately
5% of the turmeric. Curcuminoids extract contains three major compounds: curcumin
(60-70%), demethoxycurcumin (20%), and bisdemethoxycurcumin (10%). Mounting
evidence from preclinical studies over the past few decades have shown that curcumin
has a wide variety of beneficial biological activities such as anticancer, antiinflammatory, and antioxidant properties [270-273], these findings have led to more than
120 clinical studies of curcuminoids against several diseases. The attractiveness of
curcumin as a therapeutic agent is further enhanced by its safety up to 20 mg per
serving [270].
Animals and human studies indicate that systemic bioavailability of curcumin is
relatively low (less than 1%) after oral administration. For instance, after 8 g of oral
curcumin administration, the peak serum concentration was detected after 1 hour at 1.75
μM/L [274]. Furthermore, curcumin is extensively conjugated in the intestine and liver to
form curcumin glucuronide, curcumin sulfate or reduced to tetrahydrocurcumin,
hexahydrocurcumin, and octahydrocurcumi, these modifications further contribute to low
bioavailability of curcumin[275]. There is some evidence indicating that oral
administration of curcumin accumulates in gastrointestinal tissues and was detected in
both malignant and normal colorectal tissues [276], suggesting that oral administration of
curcumin is not effective for its delivery to tissues outside the gastrointestinal tract.
Several curcumin formulations are currently being explored with the aim of increased
bioavailability and targeted delivery. Examples of these approaches include
encapsulation to nanoparticles, liposomes, and micelles [277].
Curcumin is an effective scavenger of NO• and O2•– in the cell-free system [278,
279]. In skeletal muscles (L-6 myoblast), curcumin treatment reduced intracellular ROS
measured by dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay. [280], indicating
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that curcumin diffuses through the cell membrane and prevents the production of
different ROS compounds required to oxidize DCFH-DA. In humans with colorectal
cancer, orally administered curcumin (3600 mg) daily for 1 week significantly reduced
malondialdehyde-DNA adduct, which reflects oxidative DNA damage in the intestinal
mucosa [281]. In addition to the direct antioxidant property, curcumin has been shown to
induce the expression of phase II antioxidant enzymes [282]. In particular, curcumin
increases the expression of phase II antioxidant enzymes via activation of Nrf2. For
instance, in rat renal tubular epithelial cells, curcumin treatment increased expression of
Nrf2 and HO-1, whereas Nrf2 knockdown with small interfering RNA (siRNA) prevented
the curcumin-induced upregulation of HO-1 [283]. Furthermore, in mice with ethanolinduced liver injury, oral curcumin (150 mg/kg) for 6 weeks resulted in an increased
expression of Nrf2, which was associated with upregulated antioxidant enzymes and
reduced hepatic malondialdehyde [284]. Curcumin has also been shown to possess a
neuroprotective effect, which was associated with Nrf2 upregulation in mice with cerebral
ischemia [285], and has been found to prevent or reduce certain pathological features of
Alzheimer's disease in animals and human [286, 287].
In addition to its antioxidant effects, curcumin has been shown to inhibit multiple
mediators of the inflammatory response. As mentioned above, curcumin reduces
oxidative stress by reduction of malondialdehyde-DNA adduct, which is immunogenic
and initiates a pro-inflammatory response. Furthermore, the anti-inflammatory effect of
curcumin results from its ability to inhibit NF-κB pathway, as well as other proinflammatory signaling pathways [288].
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Curcumin processes several distinct chemical properties that facilitate its
biological effects (figure 1.5). The hydrogen bond donation capacity of β-dicarbonyl
moiety, hydroxy phenolics, and methoxy groups facilitate the interaction of curcumin with
amino acid residues in different protein targets. The ability of curcumin to interact and
inhibit DNA methyltransferase is relevant to the anticancer effect of curcumin [275]. On
the other hand, the β-dicarbonyl moiety of the curcumin is thought to be responsible for
its antioxidant effect. For instance, molecules with an extra pair of electrons such as
thiols are covalently attached to the β-unsaturated dicarbonyl segment of the curcumin
[280]. As such, the covalent binding of curcumin with thiols containing proteins such as
Keap1 and subsequent Nrf2 activation likely contribute to the curcumin antioxidant
property.

Statement of the problem

Figure 1.5 - Structure of curcumin and its key function groups
Blue circle depicts polyphenol, green circles depict Micheal acceptor sites, and red circles
depict hydrogen binding sites.
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There is substantial evidence that ROS is increased in CHF and contribute to the
disease progression [107]. Ang II generated within the CNS as well as peripheral Ang II,
acting via circumventricular organs, increases ROS levels within the RVLM and at sites
that project to the RVLM, which evoke oxidative modification of neuronal constituents
such as ion channels, resulting in overactivation of sympathetic neurons [11]. Global
sympathoexcitation further damage cardiomyocytes, which leads to further increases in
the discharge sensitivity of presympathetic neurons within the RVLM creating a vicious
positive feedback cycle [58, 289].
One of the peripheral sequelae of the overactivation of the SNS is peripheral
vasoconstriction, which in the long term, becomes exaggerated and results in many
adverse skeletal muscle adaptations[290]. Such a state of chronic under perfusion,
especially during exercise, leads to a greater reliance on anaerobic metabolism and
increased oxidative stress[193]. Oxidative stress in skeletal muscle alters the
sensitization of nerve endings within skeletal muscle and further exacerbates SNS
overactivation leading to peripheral vasoconstriction creating another positive feedback
cycle. Furthermore, Increased ROS levels in skeletal muscle is associated with muscle
wasting and dysfunctional contractile machinery, which substantially contribute to
exercise intolerance [190].
Extensive work over the past two decades has identified Nrf2 as a key signaling
intermediate of several antioxidant enzymes and oxidative stress in multiple cell types
including neurons and skeletal muscle [265, 291]. Furthermore, reduced antioxidant
capacity in the RVLM and skeletal muscle substantially contribute to sympathoexcitation
and exercise intolerance [132]. While the beneficial effects of ExT in CHF are largely
attributed to its antioxidant effects, it is not known whether ExT is associated with the
upregulation of Nrf2 in the RVLM neurons in CHF condition. Furthermore, it is not clear
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whether the reduced Nrf2 expression in skeletal muscle contributes the exercise
intolerance in CHF. Therefore, we tested the hypothesis that in CHF, ExT increases
the expression of Nrf2 within the RVLM, which increased the expression of
antioxidant enzymes and reduces sympathoexcitation. Furthermore, we
hypothesized that in CHF, Nrf2 is reduced in the skeletal muscle, which
contributes to reduced antioxidant enzymes expression and exercise intolerance.
Finally, we hypothesized that upregulation of Nrf2 by curcumin would increase the
expression of antioxidant enzymes in the skeletal muscle and improved exercise
performance.

Significance of the study
Nuclear Factor E2-related Factor 2 (Nrf2) is well-known regulator of phase II
antioxidant enzymes, but its functional role has not been extensively assessed with
regard to the modulation sympatho-excitation and exercise intolerance in CHF. The
studies below suggest that impaired Nrf2 signaling is a critical mechanism underlying the
enhanced oxidative stress in the RVLM and the skeletal muscle of mice with CHF. ExT
reduces sympathoexcitation, and curcumin prevents the decline in the exercise
performance in CHF mice by upregulation of antioxidant defenses in the RVLM and
skeletal muscle respectively, likely mediated by activation of Nrf2 signaling. These
studies suggest that rather than therapeutically blocking oxidative stress, it is possible to
focus on therapeutics that upregulate Nrf2 in order to induce the production of
antioxidant enzymes. As such, these findings suggest a novel potential therapeutic
target for the reduction of sympathoexcitation and for the improvement of exercise
capacity and quality of life in CHF patients.
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Approach
To address our hypothesis, we carried out a series of in vivo physiological
cardiovascular experiments and biochemical studies. We utilized a CHF male mouse
model achieved by permanently ligating the left anterior descending artery at
approximately 8 weeks of age. This model is relevant to acute MI patients who do not
receive timely or successive reperfusion.
In order to determine exercise capacity and carry out ExT, we utilized a motor
driver treadmill, which is superior to other modalities such as swimming and running
wheel voluntary exercise. Swimming is not a nature of mice behavior and it is difficult to
define objective exhaustion criteria and the amount of work done. While the amount of
work can be quantified on both a treadmill and a running wheel, it is difficult to control
the amount of work in a running wheel, as mice are exercising voluntarily and CHF mice
may not be able to or desire to run on their own [292].

Specific aims
Aim 1: Determine whether reduced Nrf2 signaling in the RVLM contributes to
sympathoexcitation in CHF mice.
Aim 2: Identify the role of ExT on the regulation of Nrf2 in the RVLM of CHF mice
and its impact on sympathoexcitation.
Aim 3: Investigate whether suppressed Nrf2 signaling in skeletal muscle
contributes to exercise intolerance in CHF mice.
Aim 4: Determine whether curcumin (Nrf2 activator) improves exercise capacity
in mice with CHF.
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Each objective will be introduced in the subsequent chapters, with each chapter contain
a brief introduction, detailed method and discussion of major findings. A final
comprehensive discussion will follow, which will provide a cohesive overview of major
findings and implication of the dissertation. A schematic of the objectives is presented in
figure 1.6.

.

Figure 1.6 - Schematic diagram of the dissertation aims
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CHAPTER II: EXERCISE TRAINING UPREGULATES Nrf2
PROTEIN IN THE ROSTRAL VEMTROLATERAL
MEDULLA OF MICE WITH HEART FAILURE
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INTRODUCTION
As mentioned in the preceding section, ROS are increased, whereas the
expression and activity of antioxidant enzymes are reduced in the RVLM of animals with
CHF [113, 133]. Because oxidative stress in RVLM neurons results in a state of neuronal
sensitization and enhanced excitability [58], the decreased expression [133] and activity
[293] of the antioxidant enzymes in the RVLM may be a key mechanism by which
sympathoexcitation occurs in CHF. However, it remains to be seen what upstream
mechanisms mediate altered expression of the antioxidant defense system in RVLM
neurons in the CHF state.
Nuclear factor erythroid 2–related factor 2 (Nrf2) plays a key role in mediating
the transcriptional regulation of many antioxidant enzymes [254]. In a recent study [132],
our lab found that selective deletion of the Nrf2 gene in the RVLM of normal mice
resulted in downregulation of HO-1, NQO1, SOD2, and catalase protein expression and
an elevation of superoxide and ROS in the RVLM. These mice also display a sustained
increase in blood pressure, sympathoexcitation, and impaired baroreflex function.
Furthermore, in CHF mice, Nrf2 upregulation in the RVLM enhanced NQO1, and HO-1
expression reduced sympathetic nerve activity and improved baroreflex function [294].
These studies suggest that Nrf2 may be an important target for autonomic modulation in
the CHF condition.
Mounting evidence indicates that ExT normalizes sympathetic outflow and
arterial baroreflex function in CHF [155, 295, 296]. These beneficial effects are
accompanied by upregulation of antioxidant enzyme expression in the RVLM [133].
However, the precise mechanism that converts the act of ExT into a change in the
expression of antioxidant enzymes in the RVLM remains to be elucidated. Furthermore,
increasing evidence indicates that Nrf2 signaling plays a key role in how oxidative stress
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mediates the beneficial effects of ExT. Regular ExT evokes an episodic increase in
oxidative stress, leading to the upregulation of endogenous antioxidant defenses and
overall greater ability to counteract oxidative stress [258]. These findings provide further
rationale for Nrf2 modulation in RVLM in response to ExT.
We, therefore, aimed to investigate the effect of ExT on Nrf2 expression in the
RVLM in the CHF state. We hypothesized that ExT increases Nrf2 expression,
which subsequently increases antioxidant enzymes and reduces sympathetic
nerve activity associated with CHF.

51

METHODS
Animal preparation
All animal experiments in this study were approved by the Institutional Animal
Care and Use Committee at the University of Nebraska Medical Center. These
experiments were carried out under the guidelines of the National Institute of Health
Guide for the Care and Use of Laboratory Animals.
C57BL/6J mice were purchased from Jackson laboratory (Bay Harbor, ME) at 8
weeks of age and allowed to acclimate at the University of Nebraska Medical Center
animal facility for one week. Food and water were provided ad libitum, and the mice
were maintained on a 12:12-h light-dark cycle. For induction and maintenance of
anesthesia, isoflurane (2%) was administered via inhalation, and Buprenorphine (0.05
mg/kg) was provided on the day of surgery and for 3 days post-surgery to reduce pain.
Because almost all published studies regarding the effect of ExT on cardiovascular
disease have utilized male mice, we chose this gender, which allows for comparison with
the current literature. We recognize however, that there may be sex differences in
response to ExT [297, 298].
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Because of the small amount of RVLM tissue available from individual animals,
multiple cohorts were used in this study (Table 2.1), which can be summarized as
follows: morphological and Nrf2/NQO-1 immunoblotting data (Sham-Sed, n = 6; ShamExT, n = 5; CHF-Sed, n = 6; CHF-ExT, n = 4); Nrf2 and NQO-1 mRNA data (Sham Sed,
n = 6; Sham-ExT, n = 6; CHF-Sed, n = 5; CHF-ExT, n = 6); echocardiography data
(Sham-Sed, n = 5; Sham-ExT, n = 6; CHF-Sed, n = 6; CHF-ExT, n = 5); hemodynamic
data (Sham-Sed, n = 5; Sham-ExT, n = 6; CHF-Sed, n = 6; CHF-ExT, n = 7).

Cohort number

Mice groups

Experiment

•
•
•
•

Sham Sed
Sham ExT
CHF-Sed
CHF-ExT

•

2

•
•
•
•

Sham Sed
Sham ExT
CHF-Sed
CHF-ExT

•

Nrf2 and NQO-1
mRNA in the
RVLM punches

3

•
•
•
•

Sham Sed
Sham ExT
CHF-Sed
CHF-ExT

•

•

Nrf2 and NQO-1
protein
expression in the
RVLM punches
Urine NE
excretion
Plasma NE

•

Baroreflex

1

•

•

4

•
•
•
•

Sham Sed
Sham ExT
CHF-Sed
CHF-ExT

Table 2.1 - Summary of the experiments for different cohorts of mice

Nrf2 protein
expression in the
whole brain stem
Citrate synthase
in soleus muscle
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Model of CHF
Chronic HF was induced by permanent left anterior descending coronary artery
ligation, as previously described [76]. Briefly, under 2% isoflurane anesthesia, mice were
intubated and ventilated using a mechanical respirator (Mouse Ventilator miniVent model
845, Harvard Apparatus; tidal volume: 150 ul; frequency: 200 breaths/min) throughout
the surgery. A thoracotomy was performed between the 4th and 5th intercostal space to
expose the heart. In the CHF group, the left anterior descending branch of the coronary
artery was permanently ligated with 7-0 suture. After these procedures, the lungs were
re-inflated, the chest was closed with 6-0 suture, and the skin was closed with 4-0
suture. Sham mice underwent the same procedures, but the coronary artery was not
ligated. Once the animals began to recover from anesthesia, the trachea was extubated.
Mice were then placed on a 30-32 °C heating pad and room air was supplemented with
100% oxygen (1L/min into the cage) for 3 days after the surgery to improve survival rate.
Mice were assigned randomly into four groups: Sham Sedentary (Sham-Sed), sham
exercise-trained (Sham-ExT), CHF sedentary (CHF-Sed), and CHF exercise-trained
(CHF-ExT). Infarct size was determined postmortem by tracing the scar area and the
whole left ventricle (LV) using ImageJ software [National Institutes of Health (NIH),
Bethesda, MD].

Echocardiography
Four weeks after MI or sham surgery, echocardiography was carried out on all
mice. Using a 40 MHz probe, hearts were imaged on a Visual Sonics Vevo 3100
ultrasound. B-mode images were acquired in the long and short axis under isoflurane
anesthesia (1-2%). All animals were echoed when heart rates were above 400 bpm. Left
ventricular volumes and diameters were measured. Ejection fraction (EF) was calculated
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by a standard formula ((LVEDV-LVESV)/LVEDV) × 100. Fractional shortening (FS) was
calculated as ((LVEDD-LVESD)/LVEDD) × 100.

Maximal Exercise Capacity Testing
Figure 2.1A shows the general study design. After a 1-week acclimatization
period, the mice were echoed and underwent either sham or myocardial infarction
surgery. Four weeks after surgery, the mice were echoed again and subjected to an
exercise capacity test followed by aerobic training on a treadmill. After 8 weeks of
training, the mice were echoed and subjected again to exercise capacity test to evaluate
the change in exercise capacity.
Figure 2.1B shows the exercise capacity testing protocol. We performed exercise
familiarization and capacity testing as previously described [299], with minor
modifications. Mice were familiarized with a motorized treadmill (Columbus Instruments,
Columbus, OH). Familiarization consisted of a 10 min period where the treadmill and
speed were set to zero with the shock grid setting at 1.2 mA and 2 Hz. The treadmill
speed was then increased to 6 m/min on the next day for an additional 10 minutes. On
the following day, mice were subjected to an exercise capacity test, which consists of a
warm-up period at a speed of 6 m/min for 6 min. The speed was increased by 3 m/min
every 3 min at 5% inclination until exhaustion. At the termination of the test, the total
distance and the peak workload were recorded. Based on the peak workload, individual
workloads corresponding to 60% of the maximum speed were determined.
We developed strict criteria for exhaustion. These criteria include 1) 5
consecutive seconds on the electric grid without re-engaging the treadmill; 2) Inability to
keep up with the treadmill speed for 3 minutes. Every mouse was removed from his lane
once one or both criteria was reached. Following 8 weeks of training, we repeated this
test to evaluate changes in exercise capacity. Distance run (meters run before
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exhaustion) and work performed (calculated as the product of body weight and vertical
distance) were recorded. The vertical distance was calculated as the product of the
distance run and the angle of inclination of the treadmill as outlined previously [300].

Exercise training
Mice assigned to exercise training groups were subjected to 8 weeks of treadmill
running at 60% of the maximal workload achieved during the initial exercise capacity
test. As shown in figure 2.1C, the training protocol consisted of a warm-up period at 6
m/min for 5 minutes. The training intensity was set at 14 m/min for the Sham ExT group
and 11 m/min for the CHF ExT. These intensities corresponded to 60% of the maximal.
Because exercise capacity is different in each mouse, and given that exercise
adaptations occur at an intensity corresponding to maximal lactate steady state (60% of
maximal speed), we chose to train each group at their average 60% of maximal speed
rather than similar absolute speed [301-303]. Speed was calculated for each group
during the initial exercise capacity test. A recent exercise guideline paper published this
year further supports this concept [292] Training sessions occurred between 16:00 and
18:00 hours, 5 days per week. Sedentary mice were habituated to the experimental
environment on the treadmill at 0 speed two to three days per week.

Blood lactate measurements
Venous blood lactate concentrations were obtained from the tail vein after mice
were acclimated to tail vein blood collection. Prior to the testing, ~0.7μL of blood (via tail
vein prick) was collected and placed for analysis on a handheld lactate meter (Lactate
Plus; Nova Biomedical, Waltham, MA, USA). Within one minute of test completion,
~0.7μL of blood was again collected and analyzed.
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Hemodynamics and baroreflex measurements
Under 2% isoflurane anesthesia, mice were placed on a metal heating pad in the
supine position. The appropriate level of anesthesia was determined by the absence of
reflex withdrawal to a painful stimulus such as foot pinch. The right common carotid
artery was dissected, and a pressure transducer (SPR-1000; Millar Instruments,
Houston, TX) was advanced into the ascending aorta and left ventricle for the
measurement of blood pressure (BP), left ventricular pressure (LVP), the first derivative
of LVP (dP/dt) and heart rate (HR). All signals were processed by a PowerLab data
acquisition system (Model 8S) and analyzed using LabChart 7 software (ADInstruments,
Colorado Springs, CO). The transducer was then pulled back into the aorta and left in
place to record arterial pressure. The left jugular vein was cannulated for intravenous (iv)
injections. Phenylephrine was administrated (0.2 μg/μL in 20–40 μL, IV) to increase
arterial pressure and the subsequent bradycardia was recorded.

Construction of baroreflex curves
The induced arterial baroreflex sensitivity (IBRS) was analyzed by logistic
regression over the entire pressure range after phenylephrine administration. The values
of BP and HR were acquired every 2 seconds from the threshold to the saturation points.
A sigmoid logistic regression curve was fit to the data points using the following
equation: HR = A/1 + exp[B(MAP − C)] + D where A is the HR range, B is the slope
coefficient, MAP is the mean arterial pressure, C is the pressure at the midpoint of the
range (BP50), and D is the minimum HR [304]. The peak slope (or maximum gain) was
determined by taking the first derivative of the baroreflex curve and was calculated with
the equation: Gain max=A(1)×A(2)×[1/4], where A(1) is the range and A(2) is the
average slope.
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Figure 2.2 shows the mathematical and graphical expression of the model used
to describe the arterial baroreflex by relating in a logistic form the mean arterial pressure
response and HR response. The parameters are A, range of the HR response; B, the
slope or sensitivity of reflex response; C, MAP at the midpoint of HR range; D, minimum
HR response.
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Figure 2.1 - Study design, exercise testing, and training protocols
A: Schematic of general study design. B: incremental exercise capacity testing protocol. C:
exercise training regimen including warm-up, exercise intensity, duration, and cool down.
MI, myocardial infarction.
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Figure 2.2 - A model of the arterial baroreflex
Graphical expression of the arterial baroreflex as a logistical function relating MAP to
HR.
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RVLM punches
The RVLM nuclei were isolated by microdissection of brain sections with a hollow
blunt needle using the following coordinates: 0.75 to 1.75 mm rostral to the obex, 1.25
mm lateral to the midline [305] (Figure 2.3). The RVLM punches were removed and
stored at −80°C for subsequent biochemical measurements.

mRNA expression
Total RNA was extracted using TRIZOL reagent (Invitrogen) from RVLM
punches. RNA was reverse transcribed into double-stranded cDNA using an iScript
cDNA synthesis kit (Bio-Rad Laboratories). cDNA templates (50 ng) were then subjected
to a real-time polymerase chain reaction in triplicate using a thermocycler (PTC-200
Peltier thermal cycler with CHROMO4 continuous fluorescence detector; Bio-Rad
Laboratories), and Brilliant III ultra-FastQPCRmastermix (Agilent Technologies). Mouse
Nrf2 primers (Mm.PT.58.29108649) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Mm.PT.39a.1) from the Integrated DNA Technologies (Coralville, Iowa) were
used for semi quantification of Nrf2 mRNA expression. Nrf2 mRNA was normalized to
GAPDH mRNA as Δ cycle, and then the relative expression was compared with the
control group using ΔΔ cycle threshold method for quantification with Opticon Monitor
software (Bio-Rad laboratories).

Western blot analysis
The target proteins and their antibodies were Nrf2 (ab62352 R-IgG) and NQO-1
(ab 80588 R-IgG). GAPDH (Thermo 15738 M-IgG) served as an internal loading control.
Total protein was extracted using RIPA buffer. Protein concentration was measured
using Pierce BCA protein assay kit (Thermo 23225). The protein concentration was then
adjusted by adding 4% sodium dodecyl sulfate buffer to obtain equal concentration
among the samples. 30 μg protein from each sample was loaded on a 10% SDS-PAGE
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gel before being subjected to electrophoresis. The gel was then transferred onto a
Polyvinylidene Difluoride (PVDF) membrane. The membrane was probed with the
primary antibodies of the target proteins and then with GAPDH primary antibody. After
primary antibody incubation, the membrane was probed with the secondary antibodies
followed by treatment with chemiluminescence substrate (Pierce). A UVP BioImaging
System (Epi Chemi II Darkroom, Analytik Jena US LLC, Upland, CA) was used to
visualize and analyze the protein bands. The data are presented as the target proteins
band densities divided by the GAPDH density.
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A)

B)

C)

Figure 2.3 - RVLM micro-punches
A: Gross mouse brain showing the obex location after removal of the cerebellum

B: Schematic sagittal and coronal mouse brain, taken from the Paxinos and Watson mouse atlas,
showing the location of the RVLM
C: Representative RVLM micro-punches
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Nrf2 antibody validation using a blocking peptide
Because Nrf2 is highly translationally modified, we felt it necessary to validate the
Nrf2 antibody. The Nrf2 antibody was diluted in the blocking buffer (1:1000; 10 ml) which
was equally divided into two tubes, 5 ml each. In the first tube, 2 times excess blocking
peptide (ab 167152) was added (10 ul), in the second tube, an equivalent amount of
buffer only was added. RVLM punches samples (n = 3) from normal C57BL/6 mice were
loaded on the first 3 lanes on a 10% SDS-PAG gel, the same samples were loaded
again on the next 3 lanes before subjected to electrophoresis. After the gel was
transferred into Polyvinylidene Difluoride (PVDF) membrane, the membrane was cut into
two halves; the first half, containing the 1st three lanes was incubated with the control
unblocked antibody, the second half of the membrane, containing identical samples was
incubated with the blocked antibody. The two membranes were probed with the
secondary antibodies followed by treatment with chemiluminescence substrate (Thermo
Fisher Scientific Inc, Rockford, IL). A UVP BioImaging System (Epi Chemi II Darkroom,
Analytik Jena US LLC, Upland, CA) was used to visualize and analyze the protein
bands. The data are presented as the target proteins band densities divided by the
GAPDH density.

Urinary NE
Mice were placed in metabolic cages (Harvard Apparatus, Holliston, MA) and
acclimated to the environment for 2-3 days. Urinary NE concentration was measured
using a NE Enzyme Immunoassay kit (Labor Diagnostika Nord KG, Nordhorn,
Germany). The samples were diluted 20-fold, from which 10 ul was used for NE
measurement according to the kit instructions. The sensitivity and the standard range
are 1.7 ng/ml and 5-1000 ng/ml, respectively. Each sample was measured in duplicate.
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The excretion rate was calculated by multiplying NE concentration by the 24-hour urine
volume.

Plasma NE
Blood was collected by cardiac puncture following the acute experiment. Under
2% isoflurane anesthesia, the heart was exposed via a thoracotomy by removing the
ventral segment of the 3rd to 6th ribs together with the sternum. A 21G needle
connected to 1 mL syringe was inserted into the left ventricle. Blood was withdrawn
slowly and transferred into a 1.5 mL Eppendorf tube containing 10% K EDTA (10 μl).
Blood was centrifuged at 1000 X g for 10 min at 4 °C. We were able to reliably obtain ∼1
mL blood which resulted in ∼500 μL of plasma, from which 300 μL was used to measure
the NE concentration. The sensitivity and the standard range are 0.036 ng/ml and 51000 ng/ml, respectively.

Citrate Synthase
Citrate synthase (CS) activity was carried out as previously described [306].
Briefly, left soleus muscle samples were placed on ice-cold lysis buffer (MSM-EDTA)
buffer, homogenized and centrifuged at 14000 x g for 10 minutes. The supernatants
were collected and protein concentration was measured using the Pierce bicinchoninic
acid method (Thermo Fisher Scientific Inc, Rockford, IL). The assays were carried out in
duplicate using a spectrophotometer (DU Series 640; Beckman Instruments, Fullerton,
CA). The CS activity was determined by measuring the appearance of yellow product
((5,5`-dithiobis [2-nitrobenzoic]; DTNB), which was detected spectrophotometrically by
measuring absorbance at 412 nm. The absorbance changes were measured every 15 s
over 1 min at 412 nm for determination of the CS activity. The CS activity of each
specimen was expressed as specific activity normalized to total protein (micrograms).
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Statistical analysis
All data are expressed as mean ± SEM. Ordinary 2-way ANOVA was used to
perform between-group comparisons. To perform within-group comparisons, repeated 2way ANOVA analysis was used. Tukey’s post hoc test was used for analyzing the
difference among the 4 groups using GraphPad Prism 7.03 software. A P value of < 0.05
was considered statistically significant.
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RESULTS
Bodyweight, organs weight, and morphological data
The morphological data shown in Table 2.2 are from the cohort used to measure
Nrf2 and NQO-1 proteins in RVLM punches (Sham-Sed, n= 6; sham-ExT, n=5; CHFSed, n= 6; CHF-ExT, n= 4). While the bodyweight was not different among the four
groups, the heart weight was significantly higher in CHF-Sed and CHF-ExT groups
compared with the Sham-Sed group, suggesting cardiac hypertrophy in the CHF state.
There was no detectable damage to the hearts of Sham mice, whereas CHF mice
showed marked myocardial infarcts (infarct size: 33±5.4% and 30±5.5% in the Sed and
ExT groups, respectively) (Figure 2.4A). Figure 2.4B shows the EF as a function of
infarct size. CHF mice have different infarct sizes and therefore, different cardiac
function (eg, EF, LVEDP). This relationship was linear and highly significant.
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Table 2.2 - Morphological data of exercise-trained and sedentary mice

Body weight, g

Sham-Sed
N=6
28.7 ± 0.4

Sham-ExT
N=5
29.4 ± 0.5

CHF-Sed
N=6
28.9 ± 0.8

CHF-ExT
N=4
29.5 ± 0.7

Heart weight, mg

140.3 ± 8.8

149.3 ± 6.6

239.9 ± 33.8*
(p=0.016)

248.1 ± 23.5#
(p=0.045)

Heart weight/tibial
length, mg/mm

8.3 ± 0.5

9.0 ± 0.4

14.3 ± 2.1*
(p=0.017)

14.8 ± 1.3
(p=0.055)

Wet lung weight,
mg
Infarct size, % of
LV

204.8 ± 4.1

189.6 ± 9.9

219.3 ± 8.1

202.5 ± 5.2

0

0

33.0 ± 5.4****
(p<0.0001)

30.0 ± 5.5###
(p=0.0004)

* and **** compare CHF-Sed vs sham Sed; # and ### compare CHF-ExT vs sham ExT

Body weight, g

Sham-Sed
N=6
28.7 ± 0.4

Sham-ExT
N=5
29.4 ± 0.5

CHF-Sed
N=6
28.9 ± 0.8

CHF-ExT
N=4
29.5 ± 0.7

Heart weight, mg

140.3 ± 8.8

149.3 ± 6.6

239.9 ± 33.8*
(p=0.0167)

248.1 ± 23.5#
(p=0.0454)

Heart weigh/tibial
length, mg/mm

8.3 ± 0.5

9.0 ± 0.4

14.3 ± 2.1*
(p=0.0175)

14.8 ± 1.3

Wet lung weight,
mg
Infarct size, % of
LV

204.8 ± 4.1

189.6 ± 9.9

219.3 ± 8.1

202.5 ± 5.2

0

0

33.0 ± 5.4****
(p<0.0001)

30.0 ± 5.5###
(p=0.0004)

* and **** compare CHF-Sed vs sham Sed; # and ### compare CHF-ExT vs sham ExT
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Figure 2.4 – Heart infarcts and correlation between ejection fraction
and infarction size
A: Example of LV infarct (dotted line) at 12 weeks post MI
B: Infarction size and EF correlation relationship
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Echocardiographic data
The echocardiographic data are summarized in Table 2.3. These data are
derived from the cohort used to measure Nrf2 in the whole brain stem (data not shown);
Sham-Sed, n= 5; Sham-ExT, n= 6; CHF-Sed, n= 6; CHF-ExT n= 5. In this cohort,
echocardiography was done at three-time points; before MI/Sham surgery, 4 weeks after
surgery, and 8 weeks after exercise training (Fig. 2.5). Both CHF-Sed and CHF-ExT
exhibited signs of impaired cardiac function. Ejection fraction and FS were significantly
lower in CHF animals 12 weeks after myocardial infarction compared with sham animals.
Furthermore, left ventricular volume and chamber diameter were greater in CHF animals
compared with their respective Sham groups (Figure 2.6). The left ventricular anterior
wall thickness was significantly lower in CHF animals; however, left ventricular posterior
wall thickness was not altered among the four groups. Each of the four groups showed
nearly similar EF after ExT compared with measurements before ExT, suggesting that
ExT did not influence cardiac function in this model of CHF.
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Table 2.3 - Echocardiographic data of exercise trained and sedentary mice

EF, %

Sham-Sed
N=5
60.9 ± 2.3

Sham-ExT
N=6
58.3 ± 2.1

HF-ExT
N=5
29.4 ± 3.8####
(p<0.0001)
14.6 ± 2.4##
(p=0.0044)
161 ± 23.6#
(p=0.02)
111.8 ± 24.3#
(p=0.03)
0.7 ± 0.1

1 ± 0.1

HF-Sed
N=6
23.8 ± 4.8****
(p<0.0001)
11.2± 2.7***
(p=0.0002)
192.5 ± 34.2**
(p=0.001)
153.5 ± 30.3**
(p=0.001)
0.5 ± 0.1**
(p=0.002)
0.6 ± 0.1**
(p=0.001)
0.9 ± 0.1

FS, %

31.2 ± 3.3

29.2 ± 1.9

EDV, ul

46.8 ± 11.9

63 ± 4.5

ESV, ul

26 ± 5.9

25.2 ± 2.6

LVAW;d, mm

1.1 ± 0.1

1 ± 0.1

LVAW;s, mm

1.4 ± 0.1

1.5 ± 0.1

LVPW;d, mm

0.9 ± 0.1

LVPW;s, mm

1.2 ± 0.2

1.2 ± 0.1

1.1 ± 0.1

1.2 ± 0.1

LVID;d, mm

3.5 ± 0.2

3.4 ± 0.4

6.1 ± 0.5**
(p=0.001)
LVID;s, mm
2.5 ± 0.2
2.6 ± 0.1
5.5± 0.6***
(p=0.0004)
**, ***, **** compare CHF-Sed vs sham Sed; #, ## and #### compare CHF-ExT vs sham ExT.

0.8 ± 0.1##
p=0.005)
1 ± 0.1

5.6 ± 0.4##
(0.006)
5.1 ± 0.5##
(p=0.002)

EF: ejection fraction, FS: fractional shortening, EDV: end diastolic volume, ESV: end systolic volume, LVAW:
left ventricular anterior wall, LVPW: left ventricular posterior wall, LVID: left ventricular interior diameter

P* < 0.05, P** < 0.01 and P*** < 0.001 vs sham Sed; P# < 0.05, P## < 0.01 and P### < 0.001 vs sham ExT

Table 2.3: Echocardiographic data of exercise trained and sedentary mice
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Figure 2.5 - Ejection fraction before and after MI/Sham surgery and after exercise training
Cardiac function was evaluated by echocardiography at 3 time points: before MI or sham
surgery, 4 wk after surgery, and after exercise training (ExT). Sham-Sed, n = 5; ShamExT, n = 6; CHF-Sed, n = 6; CHF-ExT, n = 5.
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Sham Sed

Sham ExT

CHF Sed

CHF ExT

Figure 2.6 - Representative M-mode, long-axis, and two-dimensional
echocardiography images of the LV from each group.
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Hemodynamic data
Hemodynamic data are shown in Table 2.4. These data are derived from two
cohorts; the first cohort was used to measure Nrf2 in the whole brain stem (data not
shown), the other cohort was used to measure Nrf2 and NQO-1 mRNA from the RVLM
punches (Sham-Sed n= 5; sham-ExT n= 6; CHF-Sed n=6; CHF-ExT n= 7). The CHFSed group exhibited a significantly elevated left ventricular end-diastolic pressure, and
lower maximal and minimal dP/dt compared with the sham-Sed group. However, there
were no significant differences in these parameters between Sham-ExT and sham-Sed
or CHF-ExT and CHF-Sed, suggesting that ExT had no effect on cardiac function in
health and CHF conditions. HR was not different among the groups, suggesting that the
changes in the above cardiac parameters were not because of alteration in the HR.
Figure 2.7 shows representative hemodynamic tracings for each group.
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Table 2.4 - Hemodynamic data of exercise-trained and sedentary mice

Sham-Sed
N=5
3.4 ± 0.8

Sham-ExT
N=6
2.8 ± 0.4

dp/dt max, mmHg/s

9067 ± 479.1

9366 ± 519.2

dp/dt min, mmHg/s

-9553 ± 695.5

-9983 ± 662.2

472 ± 35.6

466 ± 29.7

LVEDP, mmHg

Heart rate, bpm

HF-Sed
N=6
12.5 ± 1.4*
(p=0.018)
4648 ± 679.2***
(p=0.0001)
-5080 ± 866.6**
(p=0.0019)
487 ± 28.5

HF-ExT
N=7
11.6 ± 2.9#
(p=0.012)
6381 ± 487.7##
(p=0.0039)
-5475± 579.4###
(p=0.0007)
504 ± 23.9

*, ** and *** denote comparisons between CHF-Sed vs sham Sed; #, ## and ### compare CHF-ExT vs sham
ExT; LVEDP: left ventricular end diastolic pressure
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Sham-Sed

Sham-ExT

CHF-Sed

0.7 s

CHF-ExT

Figure 2.7 - Representative hemodynamic tracings.
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Baroreflex parameters
Figure 2.8 shows an original recording for arterial baroreflex function in an acute
anesthetized preparation. The recording clearly shows that the changes in HR response
(bradycardia) was blunted in CHF-Sed mice and it was partially restored in CHF ExT
mouse. Composite arterial baroreflex curves and gain curves for the control of HR in the
4 groups of mice are shown in figure 2.9. The group data indicate a significant
attenuation of HR range and maximal gain in CHF mice. The attenuated HR response
and maximal were restored by ExT.
Baroreflex parameters are quantified in figure 2.10, which shows that the HR
range, MAP at the midpoint of HR range, bradycardia response, and the maximal gain
were blunted in the CHF sed group. These attenuated responses were partially restored
by ExT
Figure 2.11 shows that despite similar increases in MAP the decrease in the HR
the response to phenylephrine was essentially abolished in the CHF-Sed group, most
likely indicating a dramatic reduction in vagal tone. This decrease in the HR response
was significantly improved by ExT.
Collectively, the baroreflex data indicate that ExT did not affect baroreflex
sensitivity in Sham mice. The improvement in the baroreflex function after ExT was
largely due to an enhancement of minimum HR achieved after the administration of
phenylephrine.
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PE (5 ug)

Sham Sed

Sham ExT

CHF Sed

7 min

CHF Sed

Figure 2.8 - Representative baroreflex tracing of blood pressure and heart rate.
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Figure 2.9 - Baroreflex function and gain curves.
Composite arterial baroreflex and gain curves of arterial baroreflex function for HR
** denotes comparison between CHF Sed vs Sham Sed; # and ## demotes comparison between
CHF-ExT vs CHF-Sed
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A)

B)

C)

D)

Figure 2.10 - Mean and individual baroreflex parameters
A: Range
B: MAP at midpoint of HR range
C: minimum HR response
D: maximal gain
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Figure 2.11 - Change in MAP and HR after phenylephrine iv injection
A: change in the MAP response
B: Change in the HR response
C: Baroreflex sensitivity evaluated as bradycardia response to the increase in
the MAP.
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Exercise capacity (work performance)
To document a training effect, mice were subjected to exercise capacity testing.
Exercise capacity was evaluated at two-time points, 0, and 8 weeks post-ExT. These
time points correspond to 4- and 12-weeks post MI/Sham surgery. As shown in figure
2.12 A, Sham mice exhibited a significantly higher level of work after 8 weeks of ExT.
While there was a trend for a higher work level in the CHF-ExT group, it did not reach
significance. The sedentary groups of Sham and CHF mice showed either no
improvement or a lower capacity over time. While the absolute work level after ExT was
not different among the groups, the delta change in the work level was significantly
higher in the exercise groups of both sham and CHF compared with their respective
sedentary groups (Figure 2.12B)
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Figure 2.12 - Work performance before and after exercise training
A: Absolute work performed before and after exercise training (ExT).
B: delta (Δ) change in the work performed before and after ExT.
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Citrate Synthase
To further confirm the training adaptation at the molecular level, we measured
CS activity in the soleus muscle (Figure 2.13). After 8 weeks of training, the CHF-ExT
group showed a significantly higher CS activity compared with the CHF-Sed group;
however, there was no difference between the CHF-Sed group compared with the

Citrate Synthase Activity
(umol DNTB / min / ug protein)

Sham-Sed groups. Citrate synthase activity was also increased in the Sham-ExT group.
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Figure 2.13 - Citrate synthase activity in soleus muscle
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Blood lactate
To further confirm the reliability of exercise testing and to rule out that
mice were noncompliant to the testing protocol, we measured blood lactate levels
prior and immediately following the exercise capacity test. In the resting
condition, the blood lactate values were similar among the groups. Following the
exercise capacity test and upon meeting exhaustion criteria, blood lactate levels
were increased 2-3 fold in each group (figure 2.14). Both resting and maximal
lactate levels are within the ranges published previously for resting conditions
and exercising at or near VO2max, respectively [302, 303].
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Figure 2.14 - Blood lactate levels in the baseline and following fatigue from
exercise testing
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Nrf2 antibody validation
Figure 2.15 shows the validation of the Nrf2 antibody (ab62352) using
immunoblotting. The bands from RVLM samples observed using Nrf2 antibody were not
present when the same blot was probed after incubation with the blocking peptide.

Figure 2.15 - Nrf2 antibody validation by immunoblot
Nrf2 bands were absent after the samples (RVLM) were incubated with the blocking
peptide.
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Nrf2 and NQO-1 protein in the RVLM
In these experiments, we measured Nrf2 and one of its major target proteins
(NQO-1), in RVLM punches. As shown in figures 2.16 and 2.17, the protein expression
of both Nrf2 and NQO-1 was downregulated in the CHF state. ExT restored these
proteins to near-normal levels in the CHF state. Furthermore, ExT also upregulated both
proteins in sham mice. Nrf2 protein expression in the RVLM of mice with varying
degrees of cardiac function exhibited a positive correlation with EF (figure 2.18)
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Figure 2.16 - Nrf2 protein expression in the RVLM punches
Representative western blot (top) and relative mean data (bottom)
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Figure 2.17 - NQO-1protein expression in RVLM punches
Representative western blot (top) and relative mean data (bottom)
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Figure 2.18 - Correlation between Nrf2 protein expression in the RVLM and EF

Nrf2 and NQO-1 mRNA in the RVLM
To evaluate the mechanism by which ExT increases Nrf2 and NQO-1 proteins,
we measured their mRNA levels in the RVLM. Similar to protein data, the mRNA levels
of both Nrf2 and NQO-1 were significantly lower in the RVLM of mice with CHF. ExT
prevented downregulation of both proteins in the CHF state and upregulated both
proteins in the sham group (figure 2.19). Nrf2 mRNA in the RVLM of mice with varying
degrees of cardiac function exhibited a positive correlation with EF (figure 2.20).
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Figure 2.19 - Nrf2 and NQO-1 mRNA levels in the RVLM
.
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Figure 2.20 - Correlation between Nrf2 mRNA in the RVLM and EF

Nrf2 in visual cerebral cortex
We also evaluated the effect of ExT on Nrf2 expression in the visual cerebral
cortex, an area that does not include, to the best of our knowledge, autonomic
neurons. As shown in figure 2.21, ExT did not alter Nrf2 mRNA and protein
expression in Sham or CHF mice.
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Figure 2.21 - Nrf2 protein expression and mRNA level in visual cerebral
cortex.
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Urinary and plasma NE
As an indirect index of sympathetic nerve activity in conscious mice, urinary NE
excretion was measured 12 weeks following MI and after three days of acclimatization to
a metabolic cage. As shown in Figure 2.22, urinary NE concentration was significantly
higher in the CHF-Sed group compared with Sham Sed. ExT prevented the increase in
NE concentration. However, the urinary NE concentration may not necessarily reflect
sympathetic nerve activity, as such, we measured urinary NE excretion. The amount of
urinary volume in 24 hours was not different among groups and the increase in NE
excretion rate in CHF was prevented by Ext.
To further validate the beneficial effect of ExT on the sympathetic outflow, we
measured plasma NE. CHF-Sed mice had significantly higher plasma NE concentration.
ExT, although not statistically significant (p=0.07), prevented the increase in the plasma
NE level (figure 2.23).
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Figure 2.22 - Urinary NE levels

24 h urine volume (A), Urinary NE concentration (B), and urinary NE
excretion rate (C)
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Figure 2.23 - Plasma NE in sham and CHF groups

96

Discussion
In the present study, we tested the hypothesis that ExT increases Nrf2 and NQO1 expression in the RVLM of mice with CHF subjected to a moderate intensity ExT
regimen. This study demonstrates that Nrf2 and NQO-1 are downregulated in the RVLM
of mice with CHF, which was accompanied by elevated urinary NE excretion. ExT
normalized the expression of both Nrf2 and NQO-1, as well as urinary NE excretion.
These findings suggest that ExT in CHF activates a central Nrf2 antioxidant signaling
pathway and upregulates antioxidant enzymes to regulate redox balance and
sympathetic outflow.
Exercise training only slightly improved the increased LVEDP and the decreased
maximal rate of pressure change (dP/dtmax). ExT did not improve the decreased EF
associated with CHF. The fact that ExT did not increase cardiac function in mice with
CHF should not be unexpected. The beneficial effects of ExT in patients with CHF may
be primarily due to improvement in neurohumoral drive and therefore the cardiovascular
regulation and fluid balance [307] and peripheral blood flow. ExT also failed to improve
cardiac function of sham mice in this study. The reason for this is not clear, however it is
possible that the level of exercise training was not high enough to show changes in
young healthy mice. Alternatively, it is possible that anesthesia masks the improvement
in cardiac function as assessed by echocardiography in this group of mice. The present
study also supports the hypothesis that ExT enhances arterial baroreflex function in the
CHF state, which is in agreement with our lab’s previous findings in rats [308] and
rabbits [133] with CHF. Previous findings from our and other laboratories suggest that
ExT improves sympatho-vagal balance. For instance, our lab has previously shown that
ExT increases HR range and baroreflex gain in the unblocked state and after
sympathetic blockade with metoprolol, but not after parasympathetic blockade with
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atropine [309], indicating that augmented vagal tone to the sinoatrial node enhances
baroreflex control of HR.
Another mechanism that may also be relevant in explaining the baroreflex results
in this study is Ang II and oxidative stress. ExT has been shown to prevent the decrease
in baroreflex sensitivity in response to intracerebroventricular infusion of Ang II, which
was associated with downregulation of AT1R and NOx2 subunit protein expression in
the PVN [308]. Furthermore, enhanced baroreflex sensitivity after ExT is associated with
upregulation of antioxidant enzymes and reduced O2•– production in the RVLM of rabbits
with CHF [133].
Citrate synthase is a pace-making enzyme in the Krebs cycle. As such, it is
considered a reliable indicator of cellular aerobic metabolism [310]. After ExT, CHF-ExT
mice exhibited significantly higher activity of CS compared with CHF-Sed mice; however,
CS activity was not different at baseline in CHF-Sed compared with Sham-Sed. Despite
the fact that CHF has been characterized with skeletal myopathy [189] (usually an
advanced symptom), we did not observe a reduction in body weight or soleus weight
(data not shown) in CHF mice. Reduction of CS activity in skeletal muscle may suggest
that de novo ATP synthase during exercise is impaired, therefore, increased CS activity
in Sham-ExT (p=0.05) and CHF-ExT (p=0.006) suggest that aerobic metabolism is
improved in both trained groups. Overall, these data show a significant training effect in
both Sham and CHF mice.
Blood lactate provides a biochemical indicator of exercise-induced exhaustion at
or near VO2max [302, 303]. The rise in the blood lactate during the exercise
performance test indicates that the mice meeting the exhaustion criteria were fatigued
and not incompliant with the exercise capacity protocol.
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The RVLM is a major brain stem nucleus and considered to be a common
projection pathway of pre-sympathetic neurons descending to the spinal cord to regulate
sympathetic outflow and cardiovascular function [100, 311]. In addition, the RVLM
receives inhibitory projections from the caudal ventrolateral medulla, which modulates
arterial baroreflex regulation of sympathetic nerve activity, HR, and peripheral resistance
[312]. We have previously shown that selective deletion of the Nrf2 gene in the RVLM of
normal Nrf2 floxed mice leads to an increase in RVLM ROS levels concomitant with
downregulation of antioxidant enzymes [132]. Importantly, these mice exhibited
significant elevation of blood pressure, urinary NE and renal sympathetic nerve activity.
Conversely, ou lab laboratory has also recently shown that overexpression of Nrf2 in the
RVLM of mice with CHF reduced sympathetic outflow along with a reduction in ROS and
an increase in several Nrf2-dependent antioxidant enzymes [294]. These data strongly
suggest that in the RVLM, Nrf2 contributes to alterations in ROS, blood pressure and
sympatho-excitation. The present data showing downregulation of Nrf2 in the RVLM of
CHF mice suggests that decreased antioxidant enzymes and sympatho-excitation in
CHF may be mediated, in part, by impaired Nrf2 signaling in the RVLM. This is
consistent with previous data in the heart, where Nrf2 appears to also be downregulated
in CHF [248] and may contribute to the cardiac remodeling process [313]. However, no
studies have examined the effects of ExT on cardiac Nrf2 expression in the CHF state.
The results of this study further support increasing evidence that antioxidant
enzymes such as NQO-1 are decreased in sympatho-regulatory areas of the brain in
CHF [113, 133]. In addition, these data clearly show that ExT upregulates Nrf2 and
NQO-1 mRNA and protein expression in the RVLM of mice with CHF. Exercise may
provide a stimulus for upregulation of antioxidant enzymes in regions remote from the
exercising muscle. In addition, these data are consistent with previous reports that
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demonstrate upregulation of antioxidant enzymes in the brain, and other regions in
response to ExT [133, 314, 315]. However, the precise mechanism that converts ExT
into changes in antioxidant enzymes is not known. One possibility, for which there is a
growing body of literature, is the idea that extracellular vesicles shed from exercising
skeletal muscle can influence remote tissues, including the brain, by transferring their
cargo and regulating oxidative stress [316]. Indeed, in a recent study from our laboratory
[248] we clearly showed that exosomes released from cardiac myocytes contain
microRNAs that are specific to the translation of Nrf2.
In a review by Finkel and Holbrook [317], they propose that the best strategy to
increase antioxidant defense mechanisms may be to periodically increase sub-lethal
oxidative stress. Therefore, it is possible that some of the beneficial effects of ExT are
derived from such a stress-tolerance mechanism. One of the major benefits associated
with non-exhaustive ExT is the induction of mild oxidative stress that stimulates the
expression of antioxidant enzymes integral to several redox signaling pathways [318].
During ExT, skeletal muscle generates large amounts of ROS [319, 320] that, in part
through lipid peroxidation, may provide a stimulus for other tissues, including the RVLM.
Such a mechanism may condition pre-sympathetic neurons to cope with oxidative
stress. Presumably, this adaptation occurs because of cumulative effects of repeated
bouts of exercise on gene expression of antioxidant enzymes. The intracellular
mechanisms triggered by ExT to upregulate antioxidant enzymes are still unclear. One
possible mechanism is that exercise-associated increase in metabolic activity, probably
from mitochondria, of pre-sympathetic neurons[321] triggers ROS production, which in
turn, activates Nrf2.
There are several redox-sensitive transcription factors such as NF-kB and Nrf2
[252, 322, 323], that may be involved in the transduction mechanism by which ExT alters
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protein transcription in the brain. ExT has been shown to modulate both of these
proteins [324-326]. Previous data from the literature show that the pro-oxidant NF-kB
and antioxidant Nrf2 transcription factors compete for binding to the nuclear creb binding
protein [252]; as such, both transcription factors are critical for regulating intracellular
oxidative stress. This lab has previously shown that ExT decreased NF-kB signaling in
the brain of rabbits with CHF [133]. Although there are no studies showing this
competition in the RVLM, we speculate that in CHF, NF-kB reduces the ability of Nrf2 to
bind to the CBP, which further reduces its ability to stimulate downstream antioxidant
response elements and thus antioxidant enzymes. Data in the present study showing
upregulation of Nrf2 in the RVLM may indicate that the ExT-induced upregulation of
antioxidant enzymes is mediated, in part, by Nrf2 through restoration of the balance
between Nrf2 and NF-kB.
While the findings in this study showed an association between Nrf2 and NQO-1
in response to ExT in the CHF state, it is not completely clear if the change in the
expression of NQO-1 is mediated by Nrf2. Furthermore, we cannot determine whether
ExT-induced reduction of urinary NE excretion in CHF mice is Nrf2 dependent. To
determine whether ExT decreases sympathetic nerve activity and upregulates
antioxidant enzymes in the RVLM by a Nrf2-dependent mechanism in CHF, future
experiments on Nrf2-floxed mice treated with RVLM Cre virus will have to be carried out.
However, as indicated above [294], when Nrf2 was overexpressed in the RVLM
following the delivery of Cre virus to Keap1 floxed mice with CHF, marked sympathoinhibition was observed.
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Limitations and perspectives of the current study
One potential limitation in this study is the lack of evaluation of oxidative stress in
the RVLM. Our lab has published several papers showing that up and downregulation of
Nrf2 in the RVLM of both normal and CHF mice results in an inverse relationship
between oxidative stress and Nrf2 expression [294, 299, 308]. The fact that ExT reduces
oxidative stress is not new; a more important question is to determine whether the
reduction of oxidative stress in the RVLM after the ExT regimen in the CHF state is Nrf2dependent.
ExT in the CHF state is currently an area of intense investigation. While many
studies [327, 328] have shown that ExT is beneficial in CHF, the mechanism by which
this occurs is largely unknown. This study revealed a new potential mechanism through
which ExT upregulates antioxidant enzymes and decreases sympathetic nerve activity in
CHF. The data provided here suggest that ExT in CHF provides a stimulus for a central
mechanism through which antioxidant enzymes are normalized, most likely due to a
change in Nrf2 expression. These studies further suggest that reduction in sympathetic
nerve activity in the CHF state can be mediated through ExT or activation of the Nrf2
pathway with precisely targeted small molecule activators of Nrf2. Figure 2.24 shows an
overall summary of this study.
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Figure 2.24 - Summery and overview of the present study
A schematic of the nuclear factor erythroid 2-related factor 2 (Nrf2)/Keap1 signaling pathway
and some of the potential mechanisms by which exercise training (ExT) may impact Nrf2,
antioxidant enzymes, oxidative stress, and sympathetic nerve activity.
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CHAPTER III: CURCUMIN IMPROVES EXERCISE
PERFORMANCE OF MICE WITH CHRONIC HEART
FAILURE: Nrf2 AND ANTIOXIDANT MECHANISMS
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INTRODUCTION
Chronic heart failure is an extensive health care problem with premature death
and repeated hospitalizations. However, the burden of CHF extends beyond mortality as
it profoundly impacts the quality of life. One of the cardinal symptoms of CHF that
jeopardize independency and worsening prognosis is exercise intolerance [329, 330]
Given that CHF is characterized by left ventricular dysfunction, it was historically
presumed that the severity of cardiac dysfunction is related to the degree of intolerance
in CHF patients [330]. Subsequent studies [331, 332] showed that reduced blood flow to
skeletal muscle resulted in limited exercise capacity during incremental exercise testing.
Thus, it was presumed that the reduced cardiac output during exercise results in under
perfusion of the exercising skeletal musculature, which leads to earlier onset of
intramuscular acidosis and subsequently induced fatigue and exhaustion [333].
However, several studies showed that even after improving skeletal muscle blood flow,
exercise capacity was not improved [173, 175, 331]. Consequently, it has been
proposed that other peripheral factors, particularly skeletal muscle abnormalities, may
represent a common underlying etiology of exercise intolerance.
The significance of skeletal muscle abnormalities in CHF is that functional and
structural abnormalities are correlated with the severity of CHF [190, 193], and more
importantly with the degree of exercise intolerance. For instance, muscle mass [334],
muscle strength [335], the number of capillaries per fiber [336, 337], and ex vivo skeletal
muscle oxidative capacity [338] show a strong relationship with maximal and/or
submaximal exercise capacity. At the muscle fiber level, lower VO2max is associated
with a greater percentage of fast-twitch muscle fibers [336, 339], which have a lower
fatigue resistance. Skeletal muscle dysfunction (skeletal myopathy) is caused, in part, by
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increased ROS and/or decreased antioxidant enzymes in skeletal muscle during CHF
state. For instance, it has been demonstrated that, in the skeletal muscles of CHF
patients and animals, SODs, catalase, glutathione peroxidase, and other antioxidant
enzymes were significantly downregulated [340-342]. Skeletal muscle-specific
overexpression of SOD3 by somatic gene transfer in CHF mice significantly attenuated
muscle atrophy and dysfunction. In addition, the upregulation of antioxidant enzymes in
skeletal muscles is a principle mechanism underlying the improved exercise capacity
following exercise training in both CHF patients [340, 343] and animals [344, 345].
However, the underlying mechanism for endogenous downregulation of antioxidant
enzymes in the skeletal muscle in the CHF state is not clear. Given the evidence for the
important role of Nrf2 in antioxidant defense, we sought to establish the link between
CHF-induced exercise intolerance, alterations in antioxidant enzymes regulation, and
Nrf2. Using an integrated physiological approach, our results suggest that in skeletal
muscle, reduced Nrf2 signaling contributes to the impaired antioxidant expression, which
is associated with reduced exercise capacity. Here we chose to determine if
pharmacological activation of Nrf2 by curcumin increases the expression of
antioxidant enzymes in skeletal muscle, which is associated with improved
exercise performance.
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METHODS
Animal preparation
Forty male C57BL/6 mice 10 weeks of age were used, which were assigned to four
groups: Sham-Vehicle (Sham-Veh, n = 8), Sham-Curcumin (Sham-Cur, n = 9), CHFVehicle (CHF-Veh, n = 12), CHF-Curcumin (CHF-Cur, n = 11).

Induction of heart failure
CHF was produced by left coronary artery ligation as described in Chapter II with
modifications for this study. Although exercise intolerance is a common symptom in CHF
patients, skeletal myopathy and sarcopenia usually emerge at an advanced stage of the
disease (e.g., NYHA Class IV) [206]. Therefore, we aimed to generate CHF mice with a
large myocardial infarction (>70%) and markedly low EF (<25%). Briefly, while under
isoflurane anesthesia (~2%, 98% O2), mice were intubated and ventilated by a mouse
ventilator (tidal volume: 150−250 μl; frequency: 200 breaths/min; Mouse Ventilator
MiniVent, model no. 845; Hugo Sachs Elektronik, March-Hugstetten, Germany). The
hearts were exposed through a left thoracotomy by an incision in the fourth left
intercostal space. Instead of ligating the anterior descending branch of the left coronary
artery, a permanent ligation was made with 7.0 suture as high as possible near the aorta
to produce a large myocardial infarction. Sham mice underwent thoracotomy and
manipulation of the heart, but no coronary artery ligation was performed. This modified
method generated very severe CHF mice compared with those in our study in chapter II.
To improve the survival rate, the mice were placed in a recovery cage for three days
after surgery. A regular Micro-Isolator mouse cage (16 × 30 cm with a micro-isolator cap)
was placed on a 30–32°C heating pad and received a continuous delivery of 100%
oxygen (1 l/min) by a vinyl tube. This postoperative care remarkably reduced mortality.
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Echocardiography
Echocardiograms were carried out on all mice at four weeks post-MI or sham
surgery as described in chapter II.

Curcumin administration
Curcumin (Cur, 50 mg/kg/day) was continuously supplied with two osmotic
minipumps (AP1004, Alzet). The first pump was implanted subcutaneously in the
midscapular area at 12 weeks post-MI surgery and replaced with a new pump after 4
weeks corresponding to the useful capacity of the pump. The total duration of Cur
treatment was 8 weeks.

In vivo Experiments

Maximal Exercise Capacity Testing
Exercise capacity was tested on a mouse treadmill as described in chapter II.
Whole-body tension
Whole-body tension was used to evaluate muscle contractility in vivo, as
previously described [346]. Briefly, mice were placed in a solid polyvinyl chloride (PVC)
tube, which is 1-foot length, 1.5-inch diameter and lined with aluminum mesh from the
interior (figure 3.1). The tail of the mouse was attached to a force transducer by #1
suture, which was 5-7 cm in length. The force exerted on the transducer was recorded
by a Powerlab (ADInstruments, Inc. Colorado Springs, CO) system. In order to motivate
the mouse to move forward, the tail was stroked with a serrated forceps and the forward
pulling tension was measured. Each mouse received 10-13 strokes in 50 seconds with
about 2-4 seconds intervals between strokes. The mean value of the 5 peak readings
was used for statistical analysis.
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Gripping pad

Force Transducer

Figure 3.1 - Schematic showing whole body tension measurement
The figure shows the mouse position inside a Plexiglass tube with the tail
attached to a force transducer to determine gripping strength.
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In situ Muscle Contractility
Functional assessment of in situ Sol and EDL muscle performance was carried
out based on a modified method used for the tibialis anterior muscle [347, 348]. Figure
3.2 demonstrates in situ assessment of muscle contractility. Briefly, under ~2%
isoflurane anesthesia, mice were placed on a metal heating pad in the prone position. A
small incision on the skin above the calf was made and the Sol and EDL were identified.
The proximal tendon of the Sol and the distal tendon of the EDL were isolated, cut and
sutured with a #6 silk suture, by which the tendon was attached to a force transducer
(MLT1030/A, ADInstruments, Inc. Colorado Springs, CO). The muscle belly was
carefully kept intact with normal vasculature and innervation. A silver bipolar electrode
was inserted into the muscle belly and an intermittent tetanic stimulation with trains of
square wave pulses (2.5V, 0.3s at 50Hz per 3 sec for a total of 20 min) was delivered by
a pulse generator (A310, WPI, Inc. Sarasota, FL). During the experiment, the mice were
kept warm by an isothermal pad and heat lamp while the muscles and tendons were
moisturized by periodic wetting with saline solution.
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Figure 3.2 – Schematic of In vivo muscle contractile force measurement.
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Ex Vivo Experiments
Immunohistochemistry
Muscle fiber types and morphology were examined by immunofluorescence
staining to detect myosin heavy chain (MHC) expression as previously described [349].
In brief, after sacrifice, the Sol and EDL were harvested, embedded in O.C.T. compound
side by side, and cut into 10 um thick cryosections with a cryostat (Leica CM1850,
Germany) maintained at -20C. The sections of the mid-belly were used for
immunofluorescence staining. First, the sections were blocked with 10% goat serum in
PBS for 60 min, followed by 60 min incubation with a primary antibody cocktail (BA-F8 to
MHCI (1:50), SC-71 to MHCIIa (1:600), and BF-F3 to MHCIIb (1:100); Developmental
Studies Hybridoma Bank, University of Iowa). After washing 3 times with PBS, the
sections were incubated 60 min with a secondary antibody cocktail (Alexa Fluor 350
IgG2b (1:500), Alexa Fluor 555 IgG1 (1:500), and Alexa Fluor 488 M (1:500); Invitrogen),
followed by 3 times PBS wash. The slices were then mounted with an Aqua-Mount
mounting medium (VWR, Radno, PA), and then were examined with a laser confocal
microscope (Leica TSC STED). Cross-sectional area (CSA) was determined for each
fiber separately using ImageJ software, based on the publication by Papadopulos, et
al.[350]. Eight slices per muscle were assessed to obtain an average CSA for each type
of myofiber/muscle/mouse, which was then used for statistical analysis. The minimal
numbers of fibers analyzed in Sol/EDL were 208/24 for FI, 224/136 for FIIa, and 32/616
for FIIb.
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Western blot analyses
The skeletal muscle tissues were homogenized in RIPA buffer (50 mM TrisHCl
pH7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS), from which total protein was
extracted by centrifuging at 20000 g. The protein concentration of the extract was
measured using a protein assay kit (Pierce; Rockford, IL) and then adjusted to equal
volume in all samples with 2X 4% SDS sample buffer. The samples were boiled for 5
min and then loaded on a 7.5% SDS-PAGE gel (30 ug protein/10 ul per well) following
by electrophoresis using a Bio-Rad mini gel apparatus at 40 mA/gel for 45 min. The
fractionalized protein on the gel was electrically transferred onto a polyvinyl difluoride
membrane (Millipore). The membrane was first probed with the primary antibodies (Nrf2
ab-137550, Keap1 sc-33569, HO-1 ab-68477, NQO1 ab-80588, SOD2 sc-30080,
Catalase sc-50508, gp 91 BD-611414, ubiquitinated proteins BML-PW0930, Myogenin
sc-576, and MyoD sc-760; from Abcam, Santa Cruz Biotechnology, BD Biosciences, and
Enzo Life Sciences) and then the secondary antibody (HRP Goat Anti-Rabbit IgG
Antibody and HRP Goat anti-Mouse IgG, HRP, Thermo-Fisher Scientific). After 3 times
washing with TBST, the membrane was treated with enhanced chemiluminescence
substrate (Pierce; Rockford, IL) for 5 min. The blots on the membrane were visualized
and analyzed using a UVP BioImaging System. The membranes were then treated with
Restore Western Blot Stripping Buffer (Thermo Scientific) to remove the blots, followed
by probing with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primary
antibodies (sc-32233) or a-Tubulin (ab-64332) to get GAPDH/a-Tubulin blots as the
internal control. The final reported data are the normalized target protein band densities
by GAPDH.
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Statistical analysis
All of the data are expressed as mean ± SE. A 2-way repeated-measures
ANOVA with the Student-Newman-Keuls test was used for analyzing the differences
among the four groups. A P value of < 0.05 was taken as indicative of statistical
significance.
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RESULTS
Morphological and echocardiographic data
Table 3.1 summarizes morphological and echocardiographic measurements in
the four groups. The CHF-Veh group exhibited significantly increased heart weight,
decreased EF and FS. However, there were no differences in these parameters between
Sham-Veh and Sham-Cur or CHF-Veh and CHF-Cur, suggesting that Cur had no effects
on cardiac function in healthy and failing hearts.
Figure 3.3 shows the representative gross anatomy, heart weight,
echocardiograms, and ejection fraction from Sham and CHF mice. Compared with the
Sham hearts, the failing hearts were markedly dilated, with a ~2 fold increase in the
weight and size. The free wall of the left ventricle was almost entirely replaced by scar
tissue with an infarct size of about 80% of the LV free wall. The right ventricle and atria
were significantly enlarged and hypertrophied, a typical pathological finding in advanced
heart failure. Correspondingly, these hearts displayed significantly impaired function (EF:
17.9 % and 21.2 %) as compared with the hearts in Sham mice (EF: 69.2 % and 68.9
%).
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Table 3.1 - Morphological data of Cur and Veh treated mice

Heart weight, mg

Sham-Veh
N=8
140 ± 0.01

Sham-Cur
N=9
140 ± 0.01

CHF-Veh
N = 12
260 ± 0.04**

CHF-Cur
N = 11
280 ± 0.06##

Atria weight, mg

15.0 ± 1.0

15.5 ± 0.7

43.1 ± 3.4**

46.8 ± 2.6##

Right ventricle, mg

26.95 ± 2.6

27.85 ± 2.2

64.8** ± 6.1

69.3 ± 7.3##

Infarct size, % of
LV
Ejection Fraction,
%
Fractional
shortening, %

0

0

79.4 ± 8.9****

81.6± 6.4####

68.6 ± 8.4

67.3 ± 7.9

21.3 ± 2.1**

19.5 ± 3.3##

34.8 ± 5.5

36.1 ± 4.8

10.1 ± 2.1**

11.3 ± 1.8##

* and **** compare CHF-Veh vs sham-Veh; ## and #### compare CHF-Cur vs sham-Cur
* and **** compare CHF-Veh vs sham-Veh; ## and #### compare CHF-Cur vs sham-Cur
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Cur

Veh

Cur

Sham

CHF

Figure 3.3 - Representative hearts and echocardiograms.
Representative hearts and echocardiograms for sham-vehicle (Sh-Veh; top, left), sham-curcumin (ShCur; top, right), heart failure-vehicle (HF-Veh; bottom, left), and heart failure-curcumin (HF-Cur; bottom,
right) group. Dotted lines outline the infarct areas where the myocardium is replaced by scars. Numbers

in the bottom are not the mean data.
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Hemodynamic data
Table 3.2 summarizes hemodynamic measurements in the four groups. The
CHF-Veh group exhibited significantly elevated left ventricular end-diastolic pressure
and reduced maximal and minimal dp/dt, compared with the Sham-Veh group. However,
there were no differences in these parameters between Sham-Veh and Sham-Cur or
CHF-Veh and CHF-Cur, suggesting that Cur had no effects on cardiac function in
healthy and failing hearts. Figure 3.4 shows representative hemodynamics tracing from
each group.

Table 3.2 - Hemodynamic data of Cur and Veh treated mice

Sham-Veh
N=8
1.3 ± 1.4

Sham-Cur
N=9
0.9 ± 2.1

CHF-Veh
N = 12
29.8 ± 7.8**

CHF-Cur
N = 11
27.4 ± 6.3##

dp/dt max, mmHg/s

12138 ± 919

11198 ± 1001

dp/dt min, mmHg/s

-12952 ± 867

-12166 ± 981

2101 ± 315***
(p=0.0001)
-2540 ± 441***
(p=0.0019)

2198 ± 333###
(p=0.0039)
-2719± 462###
(p=0.0007)

LVEDP, mmHg

** and *** denote comparisons between CHF-Veh vs sham-Veh;
vs sham-Cur

##

and ### compare CHF-Cur

##

and ### compare CHF-Cur

LVEDP: left ventricular end diastolic pressure
** and *** denote comparisons between CHF-Veh vs sham-Veh;
vs sham-Cur

LVEDP: left ventricular end diastolic pressure
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Sham-Veh

Sham-Cur

CHF-Veh

0.6 s

CHF-Cur

Figure 3.4 - Representative hemodynamics tracing

119

Exercise capacity and whole-body tension
Exercise capacity was evaluated on a treadmill at three-time points, 0 (pre-), 4,
and 8 weeks post Cur treatments, correspondingly at 12, 16, and 20 weeks post-MI or at
the ages of 22, 26, and 30 weeks of age.
CHF-Veh mice displayed a significantly reduced running distance and slower
speed compared with Sham-Veh mice in all tests, validating exercise intolerance (Figure
3.5A). Sham-Cur mice exhibited an increase in maximum running distance and speed at
8 weeks compared with the baseline (at 0 week), and Sham-Veh at eight weeks,
suggesting that Cur enhanced exercise capacity in the healthy state. On the other hand,
distance and speed at eight weeks were decreased in CHF-Veh, but there was no
significant change in the CHF-Cur group as compared with the baseline at zero weeks.
Although no difference was observed between zero and eight weeks, the CHF-Cur
group exhibited significantly better exercise performance (distance and speed) at eight
weeks as compared with the CHF-Veh group, suggesting that Cur prevented the decline
in running performance in HF. During this period, no difference in body weight was found
among these groups. Figure 3.5B shows whole-body tension at eight weeks post Cur
treatment. CHF-Veh displayed a significantly lower whole-body pulling force than ShamVeh, whereas CHF-Cur had a significantly greater limb grip force than CHF-Veh.
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Figure 3.5 - Exercise performance and whole-body tension
Exercise performance [top: body weight (BW); middle: Max Dis, maximum distance; bottom: Max
Sp, maximum speed; Cur: weeks postcurcumin treatment; MI (myocardial infarction) weeks postMI surgery]. B: whole-limb grip force generation (top: original recording; bottom: mean data).
Groups are sham-vehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HFVeh, n = 12), and HF-curcumin (HF-Cur, n = 11). **P < 0.01 HF-Veh vs. Sh-Veh; @P < 0.05 HF-Cur vs.
HF-Veh; #P < 0.05 HF-Cur vs. Sh-Veh; $P < 0.05 Sh-Cur vs. Sh-Cur at 0 wk and Sh-Veh at 8 weeks.
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In situ muscle contractility
Sol and EDL muscles were selected for determination of muscle contractility in
situ because they represent typical oxidative (FI and FIIa in Sol) and glycolytic (FIIb in
EDL) muscles, respectively. Figure 3.6, Panel A is a representative time course profile of
maximal contractility during tetanic stimulation. Panel B shows representative traces of
force and force generation rate at the 1st and 400th tetanic stimuli. Panel C shows the
mean data. In Sham-Veh mice, the force developed by the Sol was maintained during
the entire period of stimulation, whereas the force of the EDL rapidly declined with time,
confirming the fatigue resistance of oxidative muscles (Sol) and fatigability of glycolytic
muscles (EDL). Curcumin had no effects on this parameter in Sham mice (Sham-Cur).
The Sol of the CHF-Veh mice displayed a similar force during the first several stimuli, but
significantly decreased with time, as compared with the Sol of the Sham-Veh. The EDL
of the CHF-Veh mice exhibited a significantly lower force in both initial and latter tetanic
stimuli compared to the EDL of Sham-Veh, suggesting dysfunction of Sol and EDL in
CHF. This muscle dysfunction in CHF was attenuated by Cur.
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Figure 3.6 – In situ Sol and EDL contractility
In situ soleus (Sol) and extensor digitorum longus (EDL) force. A: representative time course
profiles of maximal contractile response. B: representative tracings of force (red) and force
generation rate (blue) of first and last tetanus. Light green horizontal trace is the stimuli markers
(300 ms, 50 Hz). C: mean data of force generation of the first and last tetanus. Groups are shamvehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HF-Veh, n = 12), and
HF-curcumin (HF-Cur, n = 11). *P < 0.05 compared with first of Sh-Veh @P < 0.05 compared with
first of HF-Veh; #P < 0.05 compared with 400th of Sh-Veh; $P < 0.05 compared with 400th of HFVeh; %P < 0.05 compared with first of Sh-Veh and Sh-Cur.
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Immunofluorescence assessment of fiber type
Figure 3.7 shows that soleus and EDL have different fiber types and distribution.
Panel A shows that the Sol contained almost equal numbers of type I and IIa fibers, both
of which are oxidative fibers, whereas EDL was composed primarily of glycolytic type IIb
fibers. Type IIa fibers in the EDL were smaller in size compared with the IIa fibers in the
Sol. These differences in fiber composition form the well-characterized basis of
functional characteristics in Sol and EDL. Panel B of figure 3.7 shows muscle fiber
composition and size for each group. CHF-Veh mice exhibited a significant increase in
type IIa fibers and decreased type I in the Sol and decreased IIb fibers in the EDL as
compared with Sham-Veh. In addition, fiber CSA was significantly reduced in both Sol
and EDL of CHF-Veh as compared with Sham-Veh. These morphologic alterations in
CHF were attenuated by Cur.
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Figure 3.7 - Immunofluorescence staining of Soleus and EDL
Immunofluorescence staining assessment of fiber type and size in situ soleus (Sol) and extensor
digitorum longus (EDL) muscles. A: distribution of type I fibers (blue), IIa (red), and IIb (green) in
Sol and EDL of a normal mouse. Bar represents 100 μm. Representative images (B), fiber
composition (C), and fiber size (D) of Sol and EDL in the four groups of mice. Fiber-type specific
cross-sectional areas (CSAs) in a given muscle of individual animal were provided by averaging

CSAs of fibers in Sol/EDL with the numbers of FI in 208–264/24–96, FIIa in 224–560/136–392,
and FIIb in 32–64/616–872. Groups are sham-vehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n
= 9), heart failure-vehicle (HF-Veh, n = 12), and HF-curcumin (HF-Cur, n = 11). *P < 0.05 vs. ShVeh; @P < 0.05 vs. HF-Veh.
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Nrf2 and Nrf2-targeted proteins expression in Sol and EDL
Figure 3.8 shows the expression of Nrf2 and its target proteins in both muscles.
Sol and EDL exhibited differential expression profiles; Nrf2, HO-1, and GAPDH were
highly expressed in EDL, whereas SOD2 and Catalase were largely expressed in Sol.
This finding suggests a different redox status and metabolic characteristic of oxidative
and glycolytic muscles. There was no difference in the levels of Keap1, gp91, and αtubulin between these two muscle types. Compared with Sham-Veh, CHF-Veh displayed
lower Nrf2, HO-1, and SOD2 in both Sol and EDL, which were restored by Cur,
suggesting an impaired antioxidant defense in CHF and a potential beneficial effect of
Nrf2 activation on muscle antioxidant capacity. In addition, Cur upregulated Nrf2, HO-1,
and SOD2 expression in Sham mice, suggesting that Cur enhances the antioxidant
defenses even in healthy muscle. However, Cur did not affect Keap1, GAPDH, or αtubulin expression in Sham or CHF mice.
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Figure 3.8 - Nrf2 and its target proteins expression in Sol and EDL
Western blots show the expression of Nrf2 and associated proteins in soleus (Sol) and extensor
digitorum longus (EDL) of sham and heart failure with low ejection fraction (HFrEF) mice.
Downregulated nuclear factor E2-related factor 2 (Nrf2) and target proteins in muscles of HFrEF
mice were attenuated by curcumin. Cat, catalase; Keap1, Kelch-like ECH associated protein 1; HO1 hemeoxygenase; gp91, glycosylated 91-kDa glycoprotein component of flavocytochrome b558.
Groups are sham-vehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HF-

Veh, n = 12), and HF-curcumin (HF-Cur, n = 11). *P < 0.05 and **P < 0.01 vs. Sh; #P < 0.05 and ##P
< 0.01 vs. Veh; @P < 0.05 and @@P < 0.01 vs. Sol. Both bands of gp91 blot were
densitometrically analyzed.
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Ubiquitinated proteins, myogenin, and MyoD expression in Sol and EDL
Figure 3.9 shows expression of muscle proteins related to atrophy. In both
Soleus and EDL of CHF mice, total ubiquitinated proteins were significantly elevated,
suggesting an abnormal increased in the activity of UPS system. To further support this
conclusion, we measured MuRF1 and atrogen-1, two muscle-specific E3 ubiquitin ligase.
MuRF-1 is highly expressed in soleus whereas Atrogen-1 is highly expressed in EDL,
implying different mechanisms for protein degradation in oxidative and glycolytic
muscles. While Cur reduced Atrogen-1 in both sham and CHF, Atrogen-1 was not
increased in CHF compared with sham group. MuRF1 was significantly increased in
CHF in both soleus and EDL. Cur treatment prevented the increase in MuRF-1 in both
muscle in CHF state. Myogenin and MyoD are myogenic regulatory factors (transcription
factors) that regulate moyoblast differentiation into myofibers [351]. Both transcription
factors were significantly downregulated in soleus and EDL of CHF. Cur treatment
prevented downregulation of both proteins in soleus and EDL of CHF mice.
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Figure 3.9 - Ubiquitinated, Myogenin, and MyoD expression in Soleus and EDL
Expression of ubiquitinated-proteins, myogenin, and MyoD. Groups are sham-vehicle
(Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HF-Veh, n = 12),
and HF-curcumin (HF-Cur, n = 11). *P < 0.05 vs. Sh; #P < 0.05 vs. Veh; @P < 0.05 vs.

Sol.
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DISCUSSION
Exercise intolerance is a major clinical manifestation in CHF that not only worsens
prognosis, but also profoundly affects patients' quality of life [333, 352]. Ample evidence
indicates that exercise intolerance in CHF is not necessarily directly related to the
degree of cardiac dysfunction; instead it is, in part, directly related to skeletal muscle
abnormalities such atrophy, shift from type I to type II fibers, metabolic dysfunction,
impaired excitation-contraction coupling, and decreased muscle contractility [190, 290,
353]. While these pathological alterations in skeletal muscle play a critical role in CHF
symptoms such as exercise intolerance, the underlying mechanism remains to be
elucidated and pharmacological therapies are unavailable. In this study, we evaluated
therapeutic potential of antioxidant intervention on exercise intolerance in mice with
CHF. We found that CHF mice displayed markedly impaired exercise performance and
whole-body pulling force, impaired muscle contractility, and reduced fatigue-resistant
type I fiber number and size. Furthermore, we demonstrated that in CHF mice, Nrf2,
antioxidant enzymes, Myogenin, and MyoD were significantly downregulated, whereas
ubiquitinated proteins were increased. These functional impairments and morphological
abnormalities were attenuated by the chronic administration of Cur. These data suggest
that impaired Nrf2 signaling and antioxidant defenses contribute to skeletal myopathy
and that pharmacological activation of Nrf2 by Cur is a promising therapeutic strategy to
improve exercise capacity in the setting of chronic CHF. However, we did not evaluate
the oxidative status per se in animals and tissues in the present study, thus limiting our
conclusions concerning the role of and specificity of the ROS that may be involved.
Repetitive muscle contractions leads to a dramatic increase in the production of
ROS due to the high oxygen consumption in mitochondria and enhanced activity of the
electron transport chain. During aerobic exercise, skeletal muscles produce 50-100 fold
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more ROS as compared with the resting condition [354, 355], including O2 ,̄ H2O2, and OH [356-359]. These unstable molecules and ions are extremely reactive due to an
unpaired electron and highly detrimental to skeletal myocytes by promoting oxidative
reactions with proteins, lipids, and DNA [319, 360-362].
It is well established that ROS is abnormally increased in the CHF state [89,
363]. Excessive ROS not only exacerbate the failing heart but also injure peripheral
organs, such as skeletal muscle. Indeed, redox homeostasis is impaired in the skeletal
muscle of CHF animals and excessive ROS accumulates, leading to contractile
dysfunction and muscle atrophy, and the subsequent fatigue and exercise intolerance
[364, 365]. In addition to pro-oxidant processes, one particular mechanism for underlying
skeletal, myopathy in CHF is an impaired antioxidant defense system.
Increasing evidence suggests that Nrf2 participates in the redox hemostasis of
skeletal muscle and plays a critical role in skeletal muscle function. For instance, In
cultured myocytes, electrical stimulation activated Nrf2 and upregulated antioxidant
enzymes, which was abolished by Nrf2 siRNA[366]. In addition, the baseline expression
of antioxidant enzymes in skeletal muscle of Nrf2 KO mice was significantly lower than
WT mice [367]. An in situ study further demonstrated that the gastrocnemius of Nrf2 KO
mice developed more rapid fatigue and less force generation as compared with the WT
[368]. In the present study, we found that Nrf2 expression in Sol and EDL muscles was
significantly lower in CHF mice as compared with Sham, suggesting that the abovementioned dysfunction of endogenous antioxidant defenses in skeletal muscle in CHF is,
at least in part, due to impaired Nrf2 signaling. These CHF mice also displayed
significantly decreased HO-1 and SOD2 expression as well.
The balance between protein degradation and synthesis plays a crucial role in
the maintenance of skeletal muscle mass[369]. Atrophy of skeletal muscle occurs when
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protein degradation exceeds protein synthesis. In CHF, skeletal muscle breakdown,
partially due to hyperactivated ubiquitin-proteasome system, play a dominant role in
muscle wasting [370]. In skeletal muscle of CHF rats, two muscle-specific E3 ubiquitin
ligases, MuRF-1 and atrogen-1, are upregulated [371]. Administration of bortezomib, a
proteasome inhibitor, in CHF rats improves diaphragm function by restoring myosin
content via suppressing MuRF-1/atrogen-1 expression and UPS activity [372].
Importantly, apocynin, an antioxidant reagent, normalized UPS activity and prevented
skeletal muscle atrophy in CHF rats [364], suggesting a critical role of ROS in the UPSinduced skeletal myopathy. In the present study, we found a significant increase in total
ubiquitinated proteins, upregulated MuRF-1/atrogin-1, and downregulated
myogenin/MyoD in the muscle of CHF mice, confirming the contribution of UPS to
muscle atrophy in CHF state. We further found that these molecular alterations were
attenuated and accompanied by an upregulated Nrf2 after Cur administration,
suggesting Nrf2 as a potential therapeutic target of skeletal muscle atrophy in CHF.
Exercise capacity tests revealed a significantly decreased maximal distance and
speed in CHF mice as compared with sham. Overtime (from 12 to 20 weeks) post MI,
exercise capacity progressively worsened in CHF mice, suggesting that skeletal muscle
and/or cardiac function deteriorate over time. On the other hand, exercise capacity of
CHF-Cur mice did not deteriorate over time and the speed and distance were
significantly higher compared with CHF-Veh treated mice. These data suggest that Cur
prevented the decline in the exercise capacity and/or cardiac dysfunction in the CHF
state. Although Nrf2 was not evaluated in the heart, it is unlikely that Cur affects the
heart as the cardiac function was not different among the groups. We believe that the
enhanced exercise performance in CHF mice was driven primarily from the effect of Cur
on the skeletal muscle. However, given the route of Cur administration, the effect of Cur
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may extend beyond skeletal muscle and may include skeletal muscle microvasculature
and neurons. To further support our conclusion of Cur effects on skeletal muscle, we
performed a whole-body tension test, an in vivo technique to acutely evaluate skeletal
muscle force with less influence from cardiopulmonary adjustments; this test showed
that CHF-Cur treatment resulted in an increase in whole-body force as compared with
CHF-Veh treatment. Furthermore, Cur enhanced exercise capacity in sham mice,
suggesting that the beneficial effects of Cur are not exclusive to the CHF state.
We further evaluated skeletal muscle force generation and fatigue resistance
using an in situ muscle preparation. For the Sol muscle, there was no difference in the
initial force (evoked by first tetanic stimulation) between CHF-Veh and Sham-Veh,
whereas the later force (evoked by the 400th stimulation), in the CHF-Veh group was
significantly reduced compared with Sham-Veh. For EDL, both the initial and late force
were significantly reduced in the CHF-Veh group compared with the Sham-Veh group.
These abnormalities were found to be ameliorated by Cur. These data suggest that both
oxidative and glycolytic muscles from CHF mice exhibited reduced resistance to fatigue,
a possible mechanism underlying exercise intolerance. Although the Sol muscle fibers in
the CHF-Veh group exhibited a decreased CSA, the initial force production was not
decreased compared with the Sham-Veh group. This may be due to the fact that we
used a submaximal stimulation frequency (50 Hz), which could lead to a shift of the
force-frequency relationship and therefore to similar forces in atrophic muscle.
Curcumin has been shown to exerts antioxidant effects and protect mitochondria
by activating the Nrf2 pathway [373]. A growing body of evidence indicates that Cur can
limit skeletal muscle atrophy in several pathological conditions by enhancing antioxidant
defense through stimulation of the Nrf2 signaling pathway [374, 375]. Furthermore, Cur
also ameliorates exercise-induced fatigue and enhances exercise endurance in healthy
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mice [376]. This is the first study, to the best of our knowledge, that evaluated the
therapeutic potential of Cur in skeletal muscle in the CHF state. In the present study, we
demonstrated that eight weeks of Cur treatment improves exercise performance,
increases whole-body pulling force, and ameliorates skeletal myopathy in mice with
CHF, suggesting a potential application for CHF-associated skeletal myopathy. Indeed,
in patients with mitochondrial myopathy, a disease characterized skeletal muscle
weakness and exercise intolerance, the Nrf2 activator, Omaveloxolone, lowered lactate
production during submaximal exercise indicating an improvement in aerobic work
capacity and submaximal exercise capacity [377]. This improvement in aerobic capacity
can be of great value in the daily lives of patients with CHF.
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CHAPTER IV: DISCUSSION, CONCLUSION, AND
FUTURE DIRECTIONS
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Major Findings of the Dissertation
The major findings of this dissertation are:
1. Nrf2 protein is down-regulated in the RVLM of mice with CHF, which was
associated with enhanced sympathetic nerve activity.
2. Exercise training attenuated the reduction of Nrf2 in the RVLM of CHF mice,
which was associated with reduced sympathetic nerve activity.
3. Nrf2 protein is reduced in the skeletal muscle of CHF mice, which contributes to
skeletal myopathy and exercise intolerance.
4.

Curcumin upregulates Nrf2 in skeletal muscle of mice with CHF, which was
associated with improved exercise performance.

In addition to these major findings, we have provided supporting evidence for the
previously observed reduction of Nrf2 in the RVLM post-MI [294]. We have also
demonstrated that reduced Nrf2 signaling in the RVLM and skeletal muscle of CHF
mice was associated with downregulation of major antioxidant enzymes, confirming
the role of Nrf2 as a master regulator of phase II antioxidant enzymes. Given the
previous studies from our and other labs that demonstrate the key mechanistic role
of Nrf2 in mediating the expression of antioxidant enzymes in both RVLM [132, 294]
and skeletal muscle [378], it is likely that Nrf2 mediates the increase in antioxidant
enzymes in the RVLM and skeletal muscle of mice with CHF in response to ExT and
Cur treatment.
Taken together, these findings indicate that Nrf2 upregulation represents a key
link and mechanism in response to ExT and Cur treatment and enhanced
antioxidant defense in the RVLM and skeletal muscle of mice with CHF. These
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studies represent the genesis of a holistic approach against increased oxidative
stress in the CHF state.

Objectives 1-2: Nrf2 and ExT
Because downregulated antioxidant enzymes contribute, in part, to an increased
ROS in the RVLM, and given the role of an increased ROS in modulating ion channels
and enhanced sensitivity of presympathetic neurons [113, 144, 379], it is likely that
reduced expression of Nrf2 in the RVLM contributes to the sympathoexcitation in CHF
observed in this study. Since Nrf2 upregulation in the RVLM of mice with CHF
attenuates sympathoexcitation [294], and because in this study, ExT attenuated Nrf2
reduction in CHF mice, ExT-induced reduction of sympathoexcitation in CHF in this
study is likely Nrf2 dependent. The precise contribution of Nrf2 to sympathoexcitation in
response to ExT would greatly increase our ability to draw conclusions regarding the role
of Nrf2 in this pathway. These experiments, although started, were not completed due to
the slow pace of Nrf2 floxed mouse breeding and separation into CRE treated and GFP
treated Sed and ExT groups.
The fact that ExT did not improve cardiac function in mice with CHF should not
be unexpected. Although ExT is beneficial for patients with CHF [380, 381], the majority
of existing evidence suggests that Ext in the CHF state improves quality of life and
reduces mortality [382], but does not positively affect cardiac function per se [383].
Previous work from this laboratory suggests that ExT has no influence on cardiac
function[133, 384, 385] and that the more severe CHF, the less likely it is to improve
cardiac function by ExT. The present study clearly showed that ExT increased work
performance in CHF mice, an exercise adaptation likely mediated by peripheral
adaptations rather than cardiac functional improvement.
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Despite the fact that ExT had no effect on cardiac function (e.g. EF), correlative
data that relate to RVLM Nrf2 expression as a function of heart failure severity were
independent of the sedentary or exercise status of animals. We believe that these data
depict a continuum of antioxidant regulation in sympathetic neurons that is driven, in
part, by cardiac function (e.g. cardiac output). The heart, along with kidney, account for
62% of the increase in total plasma NE in CHF patients [386]. This increase In the
sympathetic drive to the heart is not only detrimental and associated with reduced
survival, but also correlates negatively with cardiac function [387].
The fact that the CS was only modestly increased in Sham-ExT does not, in our
opinion, reflect a poor exercise adaptative response. Citrate Synthase is just one
indicator and is dependent on mitochondrial function [292]. It is also possible that mice in
this group (Sham-ExT) were not stressed enough (low exercise intensity). Ideally, ExT
intensity is determined based on maximal oxygen consumption (VO2max). Because the
relationship between running speed and oxygen uptake is linear [388], we utilized
maximum running speed as a surrogate for maximal oxygen uptake.
As mentioned previously, clearly one of the major limitations in this study is the
lack of evaluation of and direct measurement of oxidative stress. However, as mentioned
in chapter II, our lab has published several papers showing 1. that up and down
regulating Nrf2 in the RVLM of both normal and heart failure animals results in an
inverse relationship between oxidative stress and Nrf2/antioxidant enzyme expression
[294] and 2. that exercise training reduces oxidative stress in the RVLM of CHF animals
[133, 308]. Another limitation is that only NQO-1 was measured in the exercise study,
despite the fact that there are dozens of Nrf2 regulated genes. Our lab has previously
shown that ExT upregulates several antioxidant enzymes in the RVLM of CHF animals
[133]. Therefore, especially with the small amount of protein extracted from the RVLM in
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mice, we felt it is unnecessary in this study to measure additional proteins to make our
point that the relationship between Nrf2 and antioxidant enzyme expression is altered by
ExT in heart failure.

Future directions
Future work will be important in expanding our understanding of the observations
in this study. Although we believe our studies have made an important contribution to the
field, numerous studies are required to further understand the role of central Nrf2 in
mediating the beneficial effects of ExT with regard to sympathetic nerve activity. Both in
vivo CHF models and cellular/molecular studies are required to closely investigate the
role of Nrf2 in the RVLM in modulating sympathetic nerve activity in response to ExT.
An important question to be addressed is what mechanisms, other than reduced
transcription, contribute to the reduced Nrf2 level in the RVLM? In this regard, enhanced
Nrf2 ubiquitination is a possible mechanism thus, co-immunoprecipitation experiments
are required. Other mechanisms for the reduced Nrf2 expression in the RVLM in the
CHF state involves NFkB. Both Nrf2 and NFkB are ROS-sensitive transcription factors,
and both have been shown to bind to the CBP in the nucleus[252]. Due to enhanced
AT1R signaling (known to occur in CHF), ROS generation, and cytokine/inflammatory
signaling [389] it is possible that increased NFkB reduces the ability of Nrf2 to bind to the
CBP in the nucleus. Given the increased Nrf2 protein in the RVLM after ExT, it is
possible that ExT reduces Nrf2 ubiquitination, reduces NFkB, and increases Nrf2 binding
to the CBP. Finally, it is possible that Nrf2 translation is regulated by changes in specific
microRNAs (e.g. 27a, 28a and 34) that are overexpressed in CHF and may be reduced
by ExT. In this regard, our laboratory has recently shown both local and remote
regulation of Nrf2 by these specific microRNAs in CHF [248, 390].
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Another question to be addressed in the future is whether ExT lowers
sympathetic nerve activity primarily or exclusively through a Nrf2-dependent mechanism.
Using animals where Nrf2 in the RVLM is deleted, it should be possible to evaluate
whether ExT has effects on oxidative stress, antioxidant enzymes, and sympathetic
nerve activity.
Increased ROS represents a link between ExT and Nrf2 activation [258]. An
important concept that needs to be addressed is the specific ROS involved in mediating
Nrf2 activation. To evaluate specific ROS that stimulate Nrf2 in response to ExT, one
strategy would be to virally transfect pre-sympathetic neurons with SOD or catalase in
CHF mice. For example, urine or plasma NE and RSNA after ExT could be measured to
evaluate if they are associated with increased or reduced Nrf2 in the RVLM. On the
other hand, because catalase is localized to the peroxisome, viral expression of catalase
may not prove that H2O2 is not involved in Nrf2 activation. Therefore, additional studies
using other H2O2 removal enzymes localized in other places in the cells such as
glutathione peroxidase, thioredoxin peroxidase, and peroxiredoxin are required to
address the role of H2O2 in Nrf2 activation in response to ExT.
In the present study, we evaluated plasma and urinary NE as an index of
increased sympathetic nerve activity in CHF. These measurements provide information
regarding the sympathetic nerve activity in mice; however, measuring sympathetic nerve
activity directly by electrophysiological techniques will provide better and more
convincing evidence of sympathoexcitation. This unfortunately was not done in this
study. Other studies from our lab have clearly shown an increase in RSNA in both
animals in the heart failure state and a decrease following exercise training [391] [133].
Furthermore, a randomized clinical trial demonstrated that ExT markedly reduced
muscle sympathetic nerve activity (measured by peroneal nerve recording) [153].
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Objectives 3-4: Curcumin, Nrf2 and exercise intolerance
Perhaps, the biggest concern about Cur is its limited bioavailability. Rodents
have been treated with Cur at doses reported to range from 10 to 1000 mg/kg/day. The
dose used in the present study was chosen based on previous studies [376, 392], in
which the Cur dose of 50 mg/kg/day was effective in improving skeletal muscle function
and exercise performance in mice. To provide a context for this dose, a dose of 20
mg/kg/day equates to approximately 4 mg/kg/day in humans based on the guide for
dose conversion between animals and humans by Nair and Jacob [393]. This dose has
been employed in clinical trials to treat cancer and inflammatory diseases [394].
Because of poor oral bioavailability of curcumin [270, 273], and because 8 weeks of ip
injections would impose undue stress, we chose to deliver Cur by osmotic minipump.
While we did not measure Cur biodistribution, a previous study [395] has shown that
plasma Cur concentrations were 0.127 ± 0.035 and 0.238 ± 0.048 ug/ml at 4 hours after
administration of 148 ug i.p. and 74 ug i.m., respectively. Plasma levels of Cur were not
detectable when 148 ug curcumin was administered by oral gavage. Given the effects of
Cur on exercise performance and skeletal myopathy, we believe that the dose (50
mg/kg/day) was adequate.
Despite the fact that Cur fully rescued Nrf2 and downstream targets, it only had a
small restorative effect on skeletal muscle performance but prevented the deterioration
of exercise performance in CHF state. These findings suggest that other mechanisms
are involved in exercise intolerance in CHF. Indeed, in addition to skeletal myopathy,
cardiovascular and pulmonary dysfunction also contribute to exercise intolerance
associated with CHF [193, 352]
The concept of skeletal muscle atrophy in CHF is disputed. Some studies [195, 396]
indicate that exercise intolerance in CHF is associated with atrophy, but not in all studies
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[397, 398] confirm this idea. One possible explanation for this discrepancy is that
skeletal muscle atrophy usually emerges in advanced CHF (class III-IV). Although the
mice in this study have more advanced CHF (perhaps mimicking class III-IV), we did not
observe a significant difference in body weight or soleus muscle weight, although there
was a trend for lower body weight in CHF mice. This may be due to the fact that muscle
atrophy is more a consequence of deconditioning or disuse [190].

Future directions
The present study suggests that Nrf2 is likely a mechanism by which Cur
prevents the decline in exercise performance in CHF. To further support a mechanistic
role of Nrf2, experiments need to be carried out in muscle-specific Nrf2 knockout mice.
For example, the effect of Cur on skeletal muscle and exercise performance could be
examined in inducible muscle-specific Nrf2 floxed mice (as iMS-Nrf2flox/flox) with the
speculation that the beneficial effects of Cur on skeletal muscle antioxidant defense and
exercise performance will be blunted after deletion of the Nrf2 gene.

Age and gender issues
Males and females exhibit a different risk for CHF. Evidence suggests that Nrf2
activation may be different between males and females[399]. Both age and gender of
the mice used in this study represent a limitation in translating this work to humans.
However, using older animals is problematic in a study like this because aging, by itself,
is associated with increased ROS levels in the brain [400] and in skeletal muscle [401].
Thus, it would be difficult, perhaps impossible, to separate CHF from aging. We could
have compared various age groups, but this would be beyond the scope of the current
dissertation.
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Synergic effects of exercise training and curcumin
Recent work has demonstrated that there is a potential synergetic effect of
combining ExT with known Nrf2 activators. For instance, synergetic effects between
Coenzyme Q10 and ExT, independent of each other, significantly increased Nrf2
expression in heart, liver, and skeletal muscle. [264]. Furthermore, Nrf2 activation
concurrent with ExT increased swimming endurance compared with ExT alone[261].
However, as mentioned in the previous sections, Cur is not only an activator for Nrf2, but
it also has a direct antioxidant property, which may interfere with ROS-induced signal
adaptation. Indeed, randomized controlled trials have shown that the health-promoting
effects of exercise such as insulin sensitivity and antioxidant defense capacity were
blocked by concurrent supplementation with Vitamins C and E [402, 403]

Conclusion and Perspectives
The major findings of this dissertation are summarized in figure 4.1. The primary
aim of this dissertation was focused on the role of Nrf2 as a potential mediator of
sympathoexcitation (objective 1) and exercise intolerance (objective 3). Furthermore, the
dissertation was also focused on the role of Nrf2 in the RVLM as a potential link between
the act of ExT and a change in autonomic activity (objective 2), as well as a link between
antioxidant enzymes and exercise performance in response to Cur administration
(objective 4). CHF is a sympathoxcitatory state associated with high mortality. In
addition, exercise intolerance is a cardinal symptom of CHF that profoundly impacts
patient’s quality of life. Ultimately, the goal of any treatment is to either improve survival
and/or improve quality of life. Although the results of the experiments in the present
study cannot be extended directly to the clinical field, the data in this study provide new
information with regard to the beneficial effects of ExT and antioxidant therapy in CHF.
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Optimal medical therapy for CHF clearly has a profound beneficial effect with
regard to the long-term outcomes. For instance, ACE inhibitors, AT1R blockers, and ß1adrenergic blockers reduce morbidity and mortality, however their effect on exercise
tolerance remains questionable [404-406]. Thus, these medications, although essential,
cannot be considered as a surrogate for ExT, which is associated with peripheral
adaptations such as increased peripheral blood flow, O2 delivery, oxidative capacity, and
increased muscle mass. These effects are translated into an increase in VO2 max, which
is associated with improved survival and better quality of life. An increase in VO2 max by
1 ml/min/kg is associated with a 9% reduction in all-cause mortality [407]. In addition,
because exercise intolerance in CHF is directly related to skeletal muscle abnormalities,
specific therapy targeting these abnormalities is important.
The interplay between the objectives of this dissertation supports the concept
that Nrf2 is an important drug target, especially with its wide spectrum of biochemical
activities.
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Figure 4.1 – Summary of the major findings in the dissertation
See text for details
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